Testhyperlink123: Difference between revisions

From GlyGen Wiki
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:


===Lewis a===
===Monosialylated===
[[File:G00047MO.png|thumb|G00047MO]]
  '''term (main_entry)''' : Monosialylated <br>
  '''term (main_entry)''' : Lewis a <br>
  '''glycan_dictionary_accession''' : GSD000123 <br>
  '''glycan_dictionary_accession''' : GSD000119 <br>
  '''glytoucan_accession ''' : <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00047MO G00047MO] <br>
  '''term_in_sentence''' : The structures of the asparagine-linked sugar chains of U- CD59 were biantennary complex type , only 4.2% of which are monosialylated.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7514386 7514386]] <br>
  '''term_in_sentence''' : Regardless of the vaccine administered, significantly fewer of the children with Lewis A phenotype (0/14) seroconverted after receiving the first vaccine dose compared to 26% (45/175) of those with the Lewis B phenotype and 32% (15/47) of the Lewis negative individuals (P < 0.01). [PMID:[https://pubmed.ncbi.nlm.nih.gov/29367698 29367698]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7514386 7514386]|[https://pubmed.ncbi.nlm.nih.gov/8477709 8477709]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/29752599 29752599]|[https://pubmed.ncbi.nlm.nih.gov/31669586 31669586]|[https://pubmed.ncbi.nlm.nih.gov/29747818 29747818]|[https://pubmed.ncbi.nlm.nih.gov/16425369 16425369]|[https://pubmed.ncbi.nlm.nih.gov/12089170 12089170]|[https://pubmed.ncbi.nlm.nih.gov/31390883 31390883]|[https://pubmed.ncbi.nlm.nih.gov/1632647 1632647]|[https://pubmed.ncbi.nlm.nih.gov/29733234 29733234]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/30555678 30555678]|[https://pubmed.ncbi.nlm.nih.gov/28263871 28263871]|[https://pubmed.ncbi.nlm.nih.gov/29652662 29652662]|[https://pubmed.ncbi.nlm.nih.gov/25915761 25915761]|[https://pubmed.ncbi.nlm.nih.gov/16381065 16381065]|[https://pubmed.ncbi.nlm.nih.gov/29247593 29247593]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/23896595 23896595]|[https://pubmed.ncbi.nlm.nih.gov/26633899 26633899]|[https://pubmed.ncbi.nlm.nih.gov/32155999 32155999]|[https://pubmed.ncbi.nlm.nih.gov/25261856 25261856]|[https://pubmed.ncbi.nlm.nih.gov/2737211 2737211]|[https://pubmed.ncbi.nlm.nih.gov/26945091 26945091]|[https://pubmed.ncbi.nlm.nih.gov/27065039 27065039]|[https://pubmed.ncbi.nlm.nih.gov/26784838 26784838]|[https://pubmed.ncbi.nlm.nih.gov/26582205 26582205] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29367698 29367698]|[https://pubmed.ncbi.nlm.nih.gov/27187324 27187324]|[https://pubmed.ncbi.nlm.nih.gov/30562693 30562693]|[https://pubmed.ncbi.nlm.nih.gov/27646625 27646625]|[https://pubmed.ncbi.nlm.nih.gov/26911286 26911286]|[https://pubmed.ncbi.nlm.nih.gov/30225822 30225822]|[https://pubmed.ncbi.nlm.nih.gov/28600306 28600306]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/32527016 32527016] [https://pubmed.ncbi.nlm.nih.gov/32527016 32527016]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2385097 2385097] [https://pubmed.ncbi.nlm.nih.gov/2385097 2385097]]|[https://pubmed.ncbi.nlm.nih.gov/11064310 11064310]|[https://pubmed.ncbi.nlm.nih.gov/23809433 23809433]|[https://pubmed.ncbi.nlm.nih.gov/30050155 30050155]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929] [https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29527514 29527514] [https://pubmed.ncbi.nlm.nih.gov/29527514 29527514]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9207264 9207264] [https://pubmed.ncbi.nlm.nih.gov/9207264 9207264]]|[https://pubmed.ncbi.nlm.nih.gov/1675497 1675497]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3677023 3677023] [https://pubmed.ncbi.nlm.nih.gov/3677023 3677023]]|[https://pubmed.ncbi.nlm.nih.gov/27705835 27705835]|[https://pubmed.ncbi.nlm.nih.gov/7593252 7593252]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2579997 2579997] [https://pubmed.ncbi.nlm.nih.gov/2579997 2579997]]|[https://pubmed.ncbi.nlm.nih.gov/17630273 17630273]|[https://pubmed.ncbi.nlm.nih.gov/9350993 9350993]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9098001 9098001] [https://pubmed.ncbi.nlm.nih.gov/9098001 9098001]] <br>
'''definition''' : A glycan that have the addition of one sialic acid residues. <br>
  '''definition''' : A lewis blood group antigen with structure beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an alpha-linkage and a galactosyl residue attached at the 3-position via a beta-linkage. It has a role as an epitope and an antigen. It is an amino trisaccharide and a glucosamine oligosaccharide.[CHEBI:62265] <br>
'''term_xref''' :  <br>
  '''term_xref''' : GTC:G00047MO|CID:[https://pubmed.ncbi.nlm.nih.gov/22806751 22806751]|CHEBI:62265|GlycoMotif:GGM.000020|SugarBind_Ligand:155 <br>
'''synonyms''' :  <br>
  '''synonyms''' : Le(a)|Lea-3|Lea|Le^a <br>
'''function''' : appears in bovine brain gangliosides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/29752599 29752599]] <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
 
 
===Monosialyl-biantennary===
'''term (main_entry)''' : Monosialyl-biantennary <br>
'''glycan_dictionary_accession''' : GSD000124 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : In contrast, the sugar chain structure of HCC highly specific AFP isoform was found to comprise a monosialyl-biantennary sugar chain with additional fucosylation of the proximal N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7686446 7686446]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7686446 7686446]|[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/9648261 9648261]|[https://pubmed.ncbi.nlm.nih.gov/10460833 10460833]|[https://pubmed.ncbi.nlm.nih.gov/19524219 19524219]|[https://pubmed.ncbi.nlm.nih.gov/10207016 10207016]|[https://pubmed.ncbi.nlm.nih.gov/15797573 15797573]|[https://pubmed.ncbi.nlm.nih.gov/15218190 15218190] <br>
  '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
  '''term_xref''' : <br>
  '''synonyms''' : monosialyl biantennary|sialylated diantennary|sialylated biantennary <br>
  '''function''' :  <br>
  '''function''' :  <br>
  '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:155] <br>
  '''disease_associations''' : <br>
  '''wikipedia''' : https://www.wikidata.org/wiki/Q[https://pubmed.ncbi.nlm.nih.gov/50687009 50687009] <br>
  '''wikipedia''' : <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>




===Lewis b===
===Monosialyl-Gb5===
[[File:G39211DH.png|thumb|G39211DH]]
[[File:G32254QI.png|thumb|G32254QI]]
  '''term (main_entry)''' : Lewis b <br>
  '''term (main_entry)''' : Monosialyl-Gb5 <br>
  '''glycan_dictionary_accession''' : GSD000120 <br>
  '''glycan_dictionary_accession''' : GSD000125 <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G39211DH G39211DH] <br>
  '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G32254QI G32254QI] <br>
  '''term_in_sentence''' : Human mannose-binding lectin preferentially binds to human colon adenocarcinoma cell lines expressing high amount of Lewis A and Lewis B antigens.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10328552 10328552]] <br>
  '''term_in_sentence''' : Thus, malignancy of MCF-7 is highly dependent on monosialyl-Gb5, and its activation of cSrc and FAK in GEM.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10328552 10328552]|[https://pubmed.ncbi.nlm.nih.gov/23408949 23408949]|[https://pubmed.ncbi.nlm.nih.gov/31927399 31927399]|[https://pubmed.ncbi.nlm.nih.gov/26601230 26601230]|[https://pubmed.ncbi.nlm.nih.gov/28279343 28279343]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/32527016 32527016] [https://pubmed.ncbi.nlm.nih.gov/32527016 32527016]]|[https://pubmed.ncbi.nlm.nih.gov/30831115 30831115]|[https://pubmed.ncbi.nlm.nih.gov/27318698 27318698]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9207264 9207264] [https://pubmed.ncbi.nlm.nih.gov/9207264 9207264]]|[https://pubmed.ncbi.nlm.nih.gov/23828675 23828675]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29527514 29527514] [https://pubmed.ncbi.nlm.nih.gov/29527514 29527514]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929] [https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2385097 2385097] [https://pubmed.ncbi.nlm.nih.gov/2385097 2385097]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2579997 2579997] [https://pubmed.ncbi.nlm.nih.gov/2579997 2579997]]|[https://pubmed.ncbi.nlm.nih.gov/25516619 25516619]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3677023 3677023] [https://pubmed.ncbi.nlm.nih.gov/3677023 3677023]]|[https://pubmed.ncbi.nlm.nih.gov/8509439 8509439]|[https://pubmed.ncbi.nlm.nih.gov/19832116 19832116]|[https://pubmed.ncbi.nlm.nih.gov/15270746 15270746]|[https://pubmed.ncbi.nlm.nih.gov/3166398 3166398]|[https://pubmed.ncbi.nlm.nih.gov/30909206 30909206]|[https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]|[https://pubmed.ncbi.nlm.nih.gov/18400963 18400963]|[https://pubmed.ncbi.nlm.nih.gov/29751628 29751628]|[https://pubmed.ncbi.nlm.nih.gov/8982241 8982241]|[https://pubmed.ncbi.nlm.nih.gov/30284922 30284922]|[https://pubmed.ncbi.nlm.nih.gov/24576035 24576035]|[https://pubmed.ncbi.nlm.nih.gov/30974776 30974776]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9098001 9098001] [https://pubmed.ncbi.nlm.nih.gov/9098001 9098001]]|[https://pubmed.ncbi.nlm.nih.gov/31768613 31768613]|[https://pubmed.ncbi.nlm.nih.gov/1651804 1651804]|[https://pubmed.ncbi.nlm.nih.gov/25428879 25428879]|[https://pubmed.ncbi.nlm.nih.gov/15946883 15946883]|[https://pubmed.ncbi.nlm.nih.gov/30298790 30298790]|[https://pubmed.ncbi.nlm.nih.gov/30544260 30544260]|[https://pubmed.ncbi.nlm.nih.gov/29197783 29197783]|[https://pubmed.ncbi.nlm.nih.gov/8632739 8632739]|[https://pubmed.ncbi.nlm.nih.gov/7679772 7679772]|[https://pubmed.ncbi.nlm.nih.gov/18666312 18666312]|[https://pubmed.ncbi.nlm.nih.gov/20231766 20231766]|[https://pubmed.ncbi.nlm.nih.gov/29922666 29922666]|95124|[https://pubmed.ncbi.nlm.nih.gov/2247887 2247887]|[https://pubmed.ncbi.nlm.nih.gov/21519121 21519121]|[https://pubmed.ncbi.nlm.nih.gov/25153235 25153235]|[https://pubmed.ncbi.nlm.nih.gov/28751211 28751211] <br>
  '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]|[https://pubmed.ncbi.nlm.nih.gov/16995838 16995838]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/27318475 27318475] [https://pubmed.ncbi.nlm.nih.gov/27318475 27318475]] <br>
'''definition''' : alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp is a linear amino hexasaccharide comprising β-D-glucose at the reducing end with at the 4-position a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety, α(2→3)-sialylated at the terminal galactosyl residue.[CHEBI:62313] <br>
'''term_xref''' : GTC:G32254QI|GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID:[https://pubmed.ncbi.nlm.nih.gov/73427363 73427363]|CHEBI:62313 <br>
'''synonyms''' : GL-7 globoseries ganglioside (SSEA-4)|Monosialyl Gb5|Sialosyl galactosyl globoside|GL-7 globoseries ganglioside|SSEA-4 <br>
'''function''' : <br>
'''disease_associations''' : renal cell carcinoma/RCC[GlycoEpitope:EP0099] <br>
'''wikipedia''' : <br>
'''essentials_of_glycobiology''' : <br>
 
 
===Mono-sulfated globopentaosylceramide===
[[File:G80193TN.png|thumb|G80193TN]]
'''term (main_entry)''' : Mono-sulfated globopentaosylceramide <br>
'''glycan_dictionary_accession''' : GSD000126 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80193TN G80193TN] <br>
'''term_in_sentence''' : Mono-sulfated globopentaosylceramide from human kidney.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2777788 2777788]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2777788 2777788] <br>
  '''definition''' :  <br>
  '''definition''' :  <br>
  '''term_xref''' : GlycoMotif:GGM.000021|SugarBind_Ligand:146|GTC:G39211DH|CID:[https://pubmed.ncbi.nlm.nih.gov/45480568 45480568]|CHEBI:59440 <br>
  '''term_xref''' : GlycoMotif:GGM.000072|GTC:G80193TN <br>
  '''synonyms''' : Le(b)|Lewis(b)|Le^b <br>
  '''synonyms''' : Monosulfated globopentaosylceramide <br>
  '''function''' : possible receptor for Helicobacter pylori[https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/blood-group-lewis-system<nowiki>] </nowiki><br>
  '''function''' : <br>
  '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:146] <br>
  '''disease_associations''' : <br>
  '''wikipedia''' :  <br>
  '''wikipedia''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
  '''essentials_of_glycobiology''' :  <br>
===Mono-sulfated globotetraosylceramide===
[[File:G05297EK.png|thumb|G05297EK]]
'''term (main_entry)''' : Mono-sulfated globotetraosylceramide <br>
'''glycan_dictionary_accession''' : GSD000127 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G05297EK G05297EK] <br>
'''term_in_sentence''' : Mono-sulfated globotetraosylceramide from human kidney.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2559078 2559078] <br>
'''definition''' :  <br>
'''term_xref''' : GlycoMotif:GGM.000073|GTC:G05297EK<br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===N-acetyl GM2===
'''term (main_entry)''' : N-acetyl GM2 <br>
'''glycan_dictionary_accession''' : GSD000128 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79389NT G79389NT] <br>
'''term_in_sentence''' : The appearance of the N-acetyl GM2 antigen correlated well with the degree of differentiation of the cancer cells in patients with squamous cell carcinoma and adenocarcinoma of the lung.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861] [https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861] [https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]]|[https://pubmed.ncbi.nlm.nih.gov/2153431 2153431]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/25673107 25673107] [https://pubmed.ncbi.nlm.nih.gov/25673107 25673107]] <br>
'''definition''' : beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp is a branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br>
'''term_xref''' : GTC:G79389NT|GlycoEpitope:EP0051|CID:[https://pubmed.ncbi.nlm.nih.gov/45266845 45266845]|CHEBI:59220 <br>
'''synonyms''' :  <br>
'''function''' : The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.[CHEBI:59220] <br>
'''disease_associations''' : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===N-acetyllactosamine (Type 1)===
[[File:G00056MO.png|alt=|thumb|G00056MO]]
'''term (main_entry)''' : N-acetyllactosamine (Type 1)<br>
'''glycan_dictionary_accession''' : GSD000181<br>
'''glytoucan_accession ''' : [https://glygen.org/glycan/G00056MO G00056MO]<br>
'''term_in_sentence''' : The N-acetyllactosamine type 1 (LacNAc type 1, Galβ1,3GlcNAc) is a well-known precursor of several important blood group epitopes, such as Lewis A, Lewis B, or sialyl Lewis A [1], which are involved in many biological processes, e.g., fertilization [2] and pathogen adhesion [3]. [PMID:[https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]]<br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28796164 28796164] [https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28167527 28167527] [https://pubmed.ncbi.nlm.nih.gov/28167527 28167527]]<br>
'''definition''' : <br>
'''term_xref''' : GTC:G00056MO|GlycoMotif:GGM.000005<br>
'''synonyms''' : LacNAc type 1|Type 1 LN|Type-1 lactosamine<br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :<br>
===N-acetyllactosamine (Type 2)===
[[File:G00055MO.png|thumb|G00055MO]]
'''term (main_entry)''' : N-acetyllactosamine (Type 2)<br>
'''glycan_dictionary_accession''' : GSD000129 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00055MO G00055MO] <br>
'''term_in_sentence''' : Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial beta1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to N-acetylglucosamine to form N-acetyllactosamine in the presence of UDP.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31165848 31165848]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31165848 31165848]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28796164 28796164]|[https://pubmed.ncbi.nlm.nih.gov/6236210 6236210]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29740087 29740087]|[https://pubmed.ncbi.nlm.nih.gov/9151975 9151975]|[https://pubmed.ncbi.nlm.nih.gov/10567443 10567443]|[https://pubmed.ncbi.nlm.nih.gov/21472942 21472942]|[https://pubmed.ncbi.nlm.nih.gov/26477523 26477523]|[https://pubmed.ncbi.nlm.nih.gov/6548353 6548353]|[https://pubmed.ncbi.nlm.nih.gov/28167527 28167527]|[https://pubmed.ncbi.nlm.nih.gov/20056550 20056550]|[https://pubmed.ncbi.nlm.nih.gov/7737204 7737204]|[https://pubmed.ncbi.nlm.nih.gov/22052010 22052010]|[https://pubmed.ncbi.nlm.nih.gov/10223649 10223649]|[https://pubmed.ncbi.nlm.nih.gov/11323440 11323440]|[https://pubmed.ncbi.nlm.nih.gov/10420596 10420596]|[https://pubmed.ncbi.nlm.nih.gov/7766648 7766648]|[https://pubmed.ncbi.nlm.nih.gov/25257940 25257940]|[https://pubmed.ncbi.nlm.nih.gov/17977857 17977857]|[https://pubmed.ncbi.nlm.nih.gov/15556936 15556936]|[https://pubmed.ncbi.nlm.nih.gov/26541999 26541999]|[https://pubmed.ncbi.nlm.nih.gov/23650594 23650594]|[https://pubmed.ncbi.nlm.nih.gov/9692202 9692202]|[https://pubmed.ncbi.nlm.nih.gov/29429899 29429899]|[https://pubmed.ncbi.nlm.nih.gov/21062783 21062783]|[https://pubmed.ncbi.nlm.nih.gov/25034434 25034434]|[https://pubmed.ncbi.nlm.nih.gov/8985145 8985145]|[https://pubmed.ncbi.nlm.nih.gov/28503789 28503789]|[https://pubmed.ncbi.nlm.nih.gov/8720464 8720464]/ <br>
'''definition''' : N-acetyllactosamine is a beta-D-galactopyranosyl-(1→4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. It is also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans.[CHEBI:16153,HMDB0001542] <br>
'''term_xref''' : GTC:G00055MO|CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001 <br>
'''synonyms''' : LacNAc|Type 2 LN <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===N-Glycolyl-GM2===
[[File:G56478LD.png|thumb|G56478LD]]
'''term (main_entry)''' : N-Glycolyl-GM2 <br>
'''glycan_dictionary_accession''' : GSD000130 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56478LD G56478LD] <br>
'''term_in_sentence''' : The monoclonal antibodies MK2-34 and MK1-16 (both IgM), which specifically detect N-glycolyl GM2 and N-acetyl GM2, respectively, were generated by immunizing mice with liposomes containing monophosphoryl lipid A, trehalose dimycolate, and the antigenic ganglioside.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861] [https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861] [https://pubmed.ncbi.nlm.nih.gov/3167861 3167861]]|[https://pubmed.ncbi.nlm.nih.gov/11861662 11861662]|[https://pubmed.ncbi.nlm.nih.gov/17980710 17980710]|[https://pubmed.ncbi.nlm.nih.gov/3731079 3731079]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/25673107 25673107] [https://pubmed.ncbi.nlm.nih.gov/25673107 25673107]] <br>
'''definition''' : (2S,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of carbohydrates and carbohydrate derivatives.[CHEBI:151464] <br>
'''term_xref''' : GTC:G56478LD |GlycoEpitope:EP0052|CID:[https://pubmed.ncbi.nlm.nih.gov/91845742 91845742]|CHEBI:151464|GlycoEpitope:GGM.000096  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' : choriocarcinoma[GlycoEpitope:EP0052]|teratocarcinoma|[GlycoEpitope:EP0052]yolk sac tumor[GlycoEpitope:EP0052] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===N-linked glycans===
[[File:G78059CC.png|thumb|G78059CC]]
'''term (main_entry)''' : N-linked glycans <br>
'''glycan_dictionary_accession''' : GSD000131 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br>
'''term_in_sentence''' : Our study identifies extracellular N-linked glycans-and the glycoprotein neurexin 1β specifically-as key modulators of neuronal uptake of αSacetyl, drawing attention to the potential therapeutic value of αSacetyl-glycan interactions.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]|[https://pubmed.ncbi.nlm.nih.gov/28384382 28384382]|[https://pubmed.ncbi.nlm.nih.gov/30305477 30305477]|[https://pubmed.ncbi.nlm.nih.gov/31364612 31364612]|[https://pubmed.ncbi.nlm.nih.gov/26899268 26899268]|[https://pubmed.ncbi.nlm.nih.gov/29945790 29945790]|[https://pubmed.ncbi.nlm.nih.gov/29652253 29652253]|[https://pubmed.ncbi.nlm.nih.gov/29723274 29723274]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/29778448 29778448]|[https://pubmed.ncbi.nlm.nih.gov/25325701 25325701]|[https://pubmed.ncbi.nlm.nih.gov/31100702 31100702]|[https://pubmed.ncbi.nlm.nih.gov/28898525 28898525]|[https://pubmed.ncbi.nlm.nih.gov/22944671 22944671]|[https://pubmed.ncbi.nlm.nih.gov/19277537 19277537]|[https://pubmed.ncbi.nlm.nih.gov/24473128 24473128]|[https://pubmed.ncbi.nlm.nih.gov/17957771 17957771]|[https://pubmed.ncbi.nlm.nih.gov/27554083 27554083]|[https://pubmed.ncbi.nlm.nih.gov/15189166 15189166]|[https://pubmed.ncbi.nlm.nih.gov/11269317 11269317]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919] [https://pubmed.ncbi.nlm.nih.gov/19577919 19577919]]|[https://pubmed.ncbi.nlm.nih.gov/24303005 24303005]|[https://pubmed.ncbi.nlm.nih.gov/12042249 12042249]|[https://pubmed.ncbi.nlm.nih.gov/22191536 22191536]|[https://pubmed.ncbi.nlm.nih.gov/28324664 28324664]|[https://pubmed.ncbi.nlm.nih.gov/25965797 25965797]|[https://pubmed.ncbi.nlm.nih.gov/25434632 25434632]|[https://pubmed.ncbi.nlm.nih.gov/30484244 30484244]|[https://pubmed.ncbi.nlm.nih.gov/28110657 28110657]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29865036 29865036] [https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/27346875 27346875]|[https://pubmed.ncbi.nlm.nih.gov/30280442 30280442]|[https://pubmed.ncbi.nlm.nih.gov/26911286 26911286]|[https://pubmed.ncbi.nlm.nih.gov/22491358 22491358]|[https://pubmed.ncbi.nlm.nih.gov/26582281 26582281]|[https://pubmed.ncbi.nlm.nih.gov/26398792 26398792]|[https://pubmed.ncbi.nlm.nih.gov/31548313 31548313]|[https://pubmed.ncbi.nlm.nih.gov/31066275 31066275]|[https://pubmed.ncbi.nlm.nih.gov/28331984 28331984]|[https://pubmed.ncbi.nlm.nih.gov/25482090 25482090]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28518173 28518173] [https://pubmed.ncbi.nlm.nih.gov/28518173 28518173]]|[https://pubmed.ncbi.nlm.nih.gov/30733536 30733536]|[https://pubmed.ncbi.nlm.nih.gov/22326428 22326428]|[https://pubmed.ncbi.nlm.nih.gov/30063825 30063825]|[https://pubmed.ncbi.nlm.nih.gov/30315103 30315103]|[https://pubmed.ncbi.nlm.nih.gov/21558494 21558494]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31676555 31676555] [https://pubmed.ncbi.nlm.nih.gov/31676555 31676555]]|[https://pubmed.ncbi.nlm.nih.gov/31256374 31256374] <br>
'''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the nitrogen of an asparagine side-chain.[CHEBI:59520] <br>
'''term_xref''' : GTC:G78059CC|CID:[https://pubmed.ncbi.nlm.nih.gov/70679232 70679232]|CHEBI:70967 <br>
'''synonyms''' :  <br>
'''function''' : N-glycans modulate the function of several cell surface proteins which involved in migration, adhesion and which are responsible for regulating myelination.[PMID: 25151374]|Affect transportation of the glycosylated proteins in the Golgi.[PMID: 25151374]|Affects cell-cell interaction, adhesion, expression, proper folding.[PMID: 25151374]|extracellular N-glycans act as key modulators of neuronal uptake of αacetyl [PMID: [https://pubmed.ncbi.nlm.nih.gov/31211781 31211781]]. <br>
'''disease_associations''' : Rheumatoid arthritis[PMID:17392038]|Type 1 Diabetes[PMID:29146600]|Lung Cancer[PMID: 23766031] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
===Nonfucosylated===
'''term (main_entry)''' : Nonfucosylated <br>
'''glycan_dictionary_accession''' : GSD000132 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : In the carbohydrate moiety , alpha-subunit from normal pregnancy hCG contained nonfucosylated , mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]]]|[https://pubmed.ncbi.nlm.nih.gov/30258536 30258536]|[https://pubmed.ncbi.nlm.nih.gov/23554380 23554380]|[https://pubmed.ncbi.nlm.nih.gov/16675584 16675584]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]|[https://pubmed.ncbi.nlm.nih.gov/22457527 22457527]|[https://pubmed.ncbi.nlm.nih.gov/24362443 24362443]|[https://pubmed.ncbi.nlm.nih.gov/19657637 19657637]|[https://pubmed.ncbi.nlm.nih.gov/8811881 8811881]|[https://pubmed.ncbi.nlm.nih.gov/19218011 19218011]|[https://pubmed.ncbi.nlm.nih.gov/20022111 20022111]|[https://pubmed.ncbi.nlm.nih.gov/17363544 17363544]|[https://pubmed.ncbi.nlm.nih.gov/17368483 17368483]|[https://pubmed.ncbi.nlm.nih.gov/20564614 20564614]|[https://pubmed.ncbi.nlm.nih.gov/27054024 27054024]|[https://pubmed.ncbi.nlm.nih.gov/28397880 28397880]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31490688 31490688] [https://pubmed.ncbi.nlm.nih.gov/31490688 31490688]]|[https://pubmed.ncbi.nlm.nih.gov/31860772 31860772]|[https://pubmed.ncbi.nlm.nih.gov/17012310 17012310]|[https://pubmed.ncbi.nlm.nih.gov/29633346 29633346]|[https://pubmed.ncbi.nlm.nih.gov/9442021 9442021]|[https://pubmed.ncbi.nlm.nih.gov/30350565 30350565]|[https://pubmed.ncbi.nlm.nih.gov/30296068 30296068]|[https://pubmed.ncbi.nlm.nih.gov/31800250 31800250]|[https://pubmed.ncbi.nlm.nih.gov/30021910 30021910]|[https://pubmed.ncbi.nlm.nih.gov/31133022 31133022]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29224385 29224385] [https://pubmed.ncbi.nlm.nih.gov/29224385 29224385]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28630087 28630087] [https://pubmed.ncbi.nlm.nih.gov/28630087 28630087]]|[https://pubmed.ncbi.nlm.nih.gov/26444434 26444434]|[https://pubmed.ncbi.nlm.nih.gov/31697975 31697975]|[https://pubmed.ncbi.nlm.nih.gov/30991260 30991260] <br>
'''definition''' : glycans without a fucose component/monosaccharide residue. <br>
'''term_xref''' :  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Nonfucosylated biantennary===
'''term (main_entry)''' : Nonfucosylated biantennary <br>
'''glycan_dictionary_accession''' : GSD000133 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : Structural analysis combining methylation-mass spectrometry and 400 MHz 1H-n.m.r. spectrometry of oligosaccharide alditols released from human leucocyte lactotransferrin shows the presence of two disialylated and non-fucosylated biantennary glycans of the N-acetyl-lactosaminic type.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2390069 2390069] [https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2390069 2390069] [https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]]]|[https://pubmed.ncbi.nlm.nih.gov/1375510 1375510]|[https://pubmed.ncbi.nlm.nih.gov/9101715 9101715]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2390069 2390069] [https://pubmed.ncbi.nlm.nih.gov/2390069 2390069]]|[https://pubmed.ncbi.nlm.nih.gov/2332109 2332109] <br>
'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
'''term_xref''' :  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9]<br>
===Nonfucosylated biantennary N-Linked structures===
'''term (main_entry)''' : Nonfucosylated biantennary N-Linked structures <br>
'''glycan_dictionary_accession''' : GSD000134 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027]]] <br>
'''definition''' : A biantennary N-linked glycan with two GlcNAc branches linked to the core and no fucose appears. <br>
'''term_xref''' :  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Nonfucosylated triantennary===
'''term (main_entry)''' : Nonfucosylated triantennary <br>
'''glycan_dictionary_accession''' : GSD000135 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/23274891 23274891] <br>
'''definition''' : A triantennary N-linked glycan with three GlcNAc branches linked to the core and no fucose appears. <br>
'''term_xref''' :  <br>
'''synonyms''' :  <br>
'''function''' : Appears in human alpha-fetoprotein (AFP).[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br>
'''disease_associations''' : hepatocellular carcinoma[PMID:[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]. <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Nonsialylated===
'''term (main_entry)''' : Nonsialylated <br>
'''glycan_dictionary_accession''' : GSD000136 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. From pooled human plasma, we find 90, 101, and 64 different glycan compositions for genetic variants ORM1*F1, ORM1*S, and ORM2, respectively. Glycan structures carry dominantly between 15 and 16 sialic acids indicating an almost complete termination of all antenae with sialic acid.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/14533820 14533820]|[https://pubmed.ncbi.nlm.nih.gov/1377689 1377689]|[https://pubmed.ncbi.nlm.nih.gov/9705949 9705949]|[https://pubmed.ncbi.nlm.nih.gov/30788437 30788437]|[https://pubmed.ncbi.nlm.nih.gov/28090561 28090561]|[https://pubmed.ncbi.nlm.nih.gov/12498371 12498371]|[https://pubmed.ncbi.nlm.nih.gov/26839900 26839900]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31490688 31490688] [https://pubmed.ncbi.nlm.nih.gov/31490688 31490688]]|[https://pubmed.ncbi.nlm.nih.gov/2656426 2656426]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31545048 31545048]|[https://pubmed.ncbi.nlm.nih.gov/12381155 12381155]|[https://pubmed.ncbi.nlm.nih.gov/25730103 25730103]|[https://pubmed.ncbi.nlm.nih.gov/26787879 26787879]|[https://pubmed.ncbi.nlm.nih.gov/25646460 25646460]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29224385 29224385] [https://pubmed.ncbi.nlm.nih.gov/29224385 29224385]]|[https://pubmed.ncbi.nlm.nih.gov/26063435 26063435]|[https://pubmed.ncbi.nlm.nih.gov/26954852 26954852]|[https://pubmed.ncbi.nlm.nih.gov/32889432 32889432]|[https://pubmed.ncbi.nlm.nih.gov/2825412 2825412]|[https://pubmed.ncbi.nlm.nih.gov/27504786 27504786]|[https://pubmed.ncbi.nlm.nih.gov/22431161 22431161] <br>
'''definition''' : A glycan which is not sialylated. <br>
'''term_xref''' :  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===O-fucose glycans===
[[File:G39294YF.png|thumb|G39294YF]]
'''term (main_entry)''' : O-fucose glycans <br>
'''glycan_dictionary_accession''' : GSD000137 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G39294YF G39294YF] <br>
'''term_in_sentence''' : Recently, a number of laboratories have shown that O-fucose glycans on the epidermal growth factor (EGF)-like repeats of the Notch extracellular domain modulate Notch signaling.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12417415 12417415]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19594638 19594638]|[https://pubmed.ncbi.nlm.nih.gov/30690220 30690220]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18952191 18952191] [https://pubmed.ncbi.nlm.nih.gov/18952191 18952191]]|[https://pubmed.ncbi.nlm.nih.gov/22415200 22415200]|[https://pubmed.ncbi.nlm.nih.gov/12417415 12417415]|[https://pubmed.ncbi.nlm.nih.gov/16400812 16400812]|[https://pubmed.ncbi.nlm.nih.gov/18948267 18948267]|[https://pubmed.ncbi.nlm.nih.gov/21464368 21464368]|[https://pubmed.ncbi.nlm.nih.gov/20816394 20816394]|[https://pubmed.ncbi.nlm.nih.gov/30207383 30207383]|[https://pubmed.ncbi.nlm.nih.gov/20301232 20301232]|[https://pubmed.ncbi.nlm.nih.gov/27129198 27129198]|[https://pubmed.ncbi.nlm.nih.gov/17132502 17132502]|[https://pubmed.ncbi.nlm.nih.gov/22492969 22492969]|[https://pubmed.ncbi.nlm.nih.gov/30030822 30030822]|[https://pubmed.ncbi.nlm.nih.gov/30214079 30214079]|[https://pubmed.ncbi.nlm.nih.gov/26175457 26175457]|[https://pubmed.ncbi.nlm.nih.gov/25378397 25378397]|[https://pubmed.ncbi.nlm.nih.gov/18272537 18272537]|[https://pubmed.ncbi.nlm.nih.gov/28729422 28729422]|[https://pubmed.ncbi.nlm.nih.gov/11524432 11524432]|[https://pubmed.ncbi.nlm.nih.gov/31722217 31722217]|[https://pubmed.ncbi.nlm.nih.gov/23045360 23045360]|[https://pubmed.ncbi.nlm.nih.gov/24803430 24803430]|[https://pubmed.ncbi.nlm.nih.gov/28876865 28876865]|[https://pubmed.ncbi.nlm.nih.gov/25700513 25700513]|[https://pubmed.ncbi.nlm.nih.gov/32518939 32518939]|[https://pubmed.ncbi.nlm.nih.gov/30523691 30523691]|[https://pubmed.ncbi.nlm.nih.gov/18227520 18227520]|[https://pubmed.ncbi.nlm.nih.gov/20816217 20816217]|[https://pubmed.ncbi.nlm.nih.gov/24909690 24909690]|[https://pubmed.ncbi.nlm.nih.gov/17964136 17964136]|[https://pubmed.ncbi.nlm.nih.gov/12036964 12036964]|[https://pubmed.ncbi.nlm.nih.gov/27268051 27268051]|[https://pubmed.ncbi.nlm.nih.gov/15653671 15653671]|[https://pubmed.ncbi.nlm.nih.gov/19948734 19948734]|[https://pubmed.ncbi.nlm.nih.gov/31590629 31590629]|[https://pubmed.ncbi.nlm.nih.gov/32201074 32201074]|[https://pubmed.ncbi.nlm.nih.gov/15189151 15189151]|[https://pubmed.ncbi.nlm.nih.gov/17263732 17263732]|[https://pubmed.ncbi.nlm.nih.gov/32913123 32913123]|[https://pubmed.ncbi.nlm.nih.gov/12909620 12909620]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176] [https://pubmed.ncbi.nlm.nih.gov/28785176 28785176]]|[https://pubmed.ncbi.nlm.nih.gov/17132500 17132500]|[https://pubmed.ncbi.nlm.nih.gov/22949680 22949680]|[https://pubmed.ncbi.nlm.nih.gov/25053492 25053492]|[https://pubmed.ncbi.nlm.nih.gov/28939751 28939751] <br>
'''definition''' : Form of glycosylation where the protein is modified by a fucose residue and can be extended futher to form a tetrasaccharide in certain cases. alpha-linked o-fucose have a consensus motif of C2X4(s/T)C3 where C2 and C3 are conserved cysteines number 2 and 3 respectively of the EGFR like repeats. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453017/ Chapter13]] <br>
'''term_xref''' : GTC:G39294YF|GlycoEpitope:EP0005<br>
'''synonyms''' :  <br>
'''function''' : modification of Notch signaling.[GlycoEpitope:EP0005] <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===O-GlcNAc===
[[File:G49108TO.png|thumb|G49108TO]]
'''term (main_entry)''' : O-GlcNAc <br>
'''glycan_dictionary_accession''' : GSD000138 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G49108TO G49108TO] <br>
'''term_in_sentence''' : A better understanding of the mechanisms of OGT/OGA action would enable us to derive therapeutic benefits of resetting cellular O-GlcNAc levels within an optimal range.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30464755 30464755]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30464755 30464755]|[https://pubmed.ncbi.nlm.nih.gov/29049853 29049853]|[https://pubmed.ncbi.nlm.nih.gov/29594839 29594839]|[https://pubmed.ncbi.nlm.nih.gov/31654859 31654859]|[https://pubmed.ncbi.nlm.nih.gov/29404877 29404877]|[https://pubmed.ncbi.nlm.nih.gov/30105004 30105004]|[https://pubmed.ncbi.nlm.nih.gov/30669087 30669087]|[https://pubmed.ncbi.nlm.nih.gov/29790000 29790000]|[https://pubmed.ncbi.nlm.nih.gov/28408483 28408483]|[https://pubmed.ncbi.nlm.nih.gov/26862193 26862193]|[https://pubmed.ncbi.nlm.nih.gov/30523150 30523150]|[https://pubmed.ncbi.nlm.nih.gov/30037904 30037904]|[https://pubmed.ncbi.nlm.nih.gov/28408480 28408480]|[https://pubmed.ncbi.nlm.nih.gov/29352075 29352075]|[https://pubmed.ncbi.nlm.nih.gov/29456783 29456783]|[https://pubmed.ncbi.nlm.nih.gov/29577901 29577901]|[https://pubmed.ncbi.nlm.nih.gov/29223644 29223644]|[https://pubmed.ncbi.nlm.nih.gov/28638491 28638491]|[https://pubmed.ncbi.nlm.nih.gov/30221662 30221662]|[https://pubmed.ncbi.nlm.nih.gov/29904918 29904918]|[https://pubmed.ncbi.nlm.nih.gov/32155042 32155042]|[https://pubmed.ncbi.nlm.nih.gov/30298013 30298013]|[https://pubmed.ncbi.nlm.nih.gov/31630803 31630803]|[https://pubmed.ncbi.nlm.nih.gov/31847126 31847126]|[https://pubmed.ncbi.nlm.nih.gov/29784830 29784830]|[https://pubmed.ncbi.nlm.nih.gov/30181664 30181664]|[https://pubmed.ncbi.nlm.nih.gov/28768194 28768194]|[https://pubmed.ncbi.nlm.nih.gov/30134155 30134155]|[https://pubmed.ncbi.nlm.nih.gov/25336654 25336654]|[https://pubmed.ncbi.nlm.nih.gov/30356792 30356792]|[https://pubmed.ncbi.nlm.nih.gov/30199580 30199580]|[https://pubmed.ncbi.nlm.nih.gov/32329777 32329777]|[https://pubmed.ncbi.nlm.nih.gov/28408494 28408494]|[https://pubmed.ncbi.nlm.nih.gov/29774032 29774032]|[https://pubmed.ncbi.nlm.nih.gov/29044951 29044951]|[https://pubmed.ncbi.nlm.nih.gov/23836420 23836420]|[https://pubmed.ncbi.nlm.nih.gov/20301273 20301273]|[https://pubmed.ncbi.nlm.nih.gov/29772801 29772801]|[https://pubmed.ncbi.nlm.nih.gov/28922739 28922739]|[https://pubmed.ncbi.nlm.nih.gov/30100348 30100348]|[https://pubmed.ncbi.nlm.nih.gov/30793403 30793403]|[https://pubmed.ncbi.nlm.nih.gov/30657688 30657688]|[https://pubmed.ncbi.nlm.nih.gov/31237748 31237748]|[https://pubmed.ncbi.nlm.nih.gov/29756380 29756380]|[https://pubmed.ncbi.nlm.nih.gov/29954943 29954943]|[https://pubmed.ncbi.nlm.nih.gov/30018219 30018219]|[https://pubmed.ncbi.nlm.nih.gov/32207184 32207184]|[https://pubmed.ncbi.nlm.nih.gov/25566193 25566193]|[https://pubmed.ncbi.nlm.nih.gov/30626734 30626734]|[https://pubmed.ncbi.nlm.nih.gov/24759912 24759912]| <br>
'''definition''' : Form of glycosylation which exclusively occurs in the mitochondrial, cytoplasmic or nuclear compartments of the cell where the protein is modified by a GlcNAc monosaccharide on the serine or threonine residues and is generally not modified or elongated further to form more complex structures. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453063/ Chapter19]] <br>
'''term_xref''' : GTC:G49108TO|GlycoEpitope:EP0004|CID:24139|HMDB:HMDB[https://pubmed.ncbi.nlm.nih.gov/0000803 0000803]  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===O-linked glycans===
'''term (main_entry)''' : O-linked glycans <br>
'''glycan_dictionary_accession''' : GSD000139 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29865036 29865036] [https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29865036 29865036] [https://pubmed.ncbi.nlm.nih.gov/29865036 29865036]]|[https://pubmed.ncbi.nlm.nih.gov/30952424 30952424]|[https://pubmed.ncbi.nlm.nih.gov/31611643 31611643]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919] [https://pubmed.ncbi.nlm.nih.gov/19577919 19577919]]|[https://pubmed.ncbi.nlm.nih.gov/32019882 32019882]|[https://pubmed.ncbi.nlm.nih.gov/19139197 19139197]|[https://pubmed.ncbi.nlm.nih.gov/26184710 26184710]|[https://pubmed.ncbi.nlm.nih.gov/11159917 11159917]|[https://pubmed.ncbi.nlm.nih.gov/21536259 21536259]|[https://pubmed.ncbi.nlm.nih.gov/25186198 25186198]|[https://pubmed.ncbi.nlm.nih.gov/19277556 19277556]|[https://pubmed.ncbi.nlm.nih.gov/22261557 22261557]|[https://pubmed.ncbi.nlm.nih.gov/24115046 24115046]|[https://pubmed.ncbi.nlm.nih.gov/18725413 18725413]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/15966855 15966855] [https://pubmed.ncbi.nlm.nih.gov/15966855 15966855]]|[https://pubmed.ncbi.nlm.nih.gov/24256304 24256304]|[https://pubmed.ncbi.nlm.nih.gov/25477510 25477510]|[https://pubmed.ncbi.nlm.nih.gov/10359703 10359703]|[https://pubmed.ncbi.nlm.nih.gov/24406064 24406064]|[https://pubmed.ncbi.nlm.nih.gov/22259135 22259135]|[https://pubmed.ncbi.nlm.nih.gov/29279989 29279989]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/15966855 15966855] [https://pubmed.ncbi.nlm.nih.gov/15966855 15966855]]|[https://pubmed.ncbi.nlm.nih.gov/30619255 30619255]|[https://pubmed.ncbi.nlm.nih.gov/9673446 9673446]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31676555 31676555] [https://pubmed.ncbi.nlm.nih.gov/31676555 31676555]]|[https://pubmed.ncbi.nlm.nih.gov/28745859 28745859]|[https://pubmed.ncbi.nlm.nih.gov/28196325 28196325]|[https://pubmed.ncbi.nlm.nih.gov/27975143 27975143]|[https://pubmed.ncbi.nlm.nih.gov/30591584 30591584]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28518173 28518173] [https://pubmed.ncbi.nlm.nih.gov/28518173 28518173]]|[https://pubmed.ncbi.nlm.nih.gov/17522109 17522109]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26328495 26328495] [https://pubmed.ncbi.nlm.nih.gov/26328495 26328495]]|[https://pubmed.ncbi.nlm.nih.gov/32178593 32178593]|[https://pubmed.ncbi.nlm.nih.gov/27529638 27529638]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/22474328 22474328]|[https://pubmed.ncbi.nlm.nih.gov/28096352 28096352]|[https://pubmed.ncbi.nlm.nih.gov/27496768 27496768]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18952191 18952191] [https://pubmed.ncbi.nlm.nih.gov/18952191 18952191]]|[https://pubmed.ncbi.nlm.nih.gov/11135308 11135308]|[https://pubmed.ncbi.nlm.nih.gov/24917611 24917611]|[https://pubmed.ncbi.nlm.nih.gov/11532966 11532966]|[https://pubmed.ncbi.nlm.nih.gov/22786570 22786570]|[https://pubmed.ncbi.nlm.nih.gov/11891229 11891229]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/26867212 26867212]|[https://pubmed.ncbi.nlm.nih.gov/26925665 26925665]|[https://pubmed.ncbi.nlm.nih.gov/16769205 16769205]|[https://pubmed.ncbi.nlm.nih.gov/23475718 23475718]|[https://pubmed.ncbi.nlm.nih.gov/16005634 16005634]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176] [https://pubmed.ncbi.nlm.nih.gov/28785176 28785176]] <br>
'''definition''' : The carbohydrate portion of a glycoprotein that has a glycan linked through the hydroxyl oxygen of serine, threonine, hydroxylysine or hydroxyproline side-chains.[CHEBI:59521] <br>
'''term_xref''' : CHEBI:59521 <br>
'''synonyms''' :  <br>
'''function''' : Affects several important activities like protein stability, modulation of signaling molecules and enzyme activity.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9673446 9673446]] <br>
'''disease_associations''' : <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===O-linked mannose===
[[File:G59126YU.png|thumb|G59126YU]]
'''term (main_entry)''' : O-linked mannose <br>
'''glycan_dictionary_accession''' : GSD000140 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G59126YU G59126YU] <br>
'''term_in_sentence''' : Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2) catalyzes the first step toward the functional matriglycan structure on alpha-dystroglycan that is responsible for binding extracellular matrix proteins and certain arenaviruses.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27932460 27932460]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27932460 27932460]|[https://pubmed.ncbi.nlm.nih.gov/24526361 24526361]|[https://pubmed.ncbi.nlm.nih.gov/25381909 25381909]|[https://pubmed.ncbi.nlm.nih.gov/26644575 26644575]|[https://pubmed.ncbi.nlm.nih.gov/23851827 23851827]|[https://pubmed.ncbi.nlm.nih.gov/28810660 28810660]|[https://pubmed.ncbi.nlm.nih.gov/19054127 19054127]|[https://pubmed.ncbi.nlm.nih.gov/23929950 23929950]|[https://pubmed.ncbi.nlm.nih.gov/21684258 21684258]|[https://pubmed.ncbi.nlm.nih.gov/22608994 22608994]|[https://pubmed.ncbi.nlm.nih.gov/28973932 28973932]|[https://pubmed.ncbi.nlm.nih.gov/24733390 24733390]|[https://pubmed.ncbi.nlm.nih.gov/31851597 31851597]|[https://pubmed.ncbi.nlm.nih.gov/29884773 29884773]|[https://pubmed.ncbi.nlm.nih.gov/28711406 28711406]|[https://pubmed.ncbi.nlm.nih.gov/14577328 14577328]|[https://pubmed.ncbi.nlm.nih.gov/21089343 21089343]|[https://pubmed.ncbi.nlm.nih.gov/14617637 14617637]|[https://pubmed.ncbi.nlm.nih.gov/9838223 9838223]|[https://pubmed.ncbi.nlm.nih.gov/17072003 17072003]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26328495 26328495] [https://pubmed.ncbi.nlm.nih.gov/26328495 26328495]]|[https://pubmed.ncbi.nlm.nih.gov/11181560 11181560]|[https://pubmed.ncbi.nlm.nih.gov/31949166 31949166]|[https://pubmed.ncbi.nlm.nih.gov/31988979 31988979]|[https://pubmed.ncbi.nlm.nih.gov/20362685 20362685]|[https://pubmed.ncbi.nlm.nih.gov/27733679 27733679]|[https://pubmed.ncbi.nlm.nih.gov/27493216 27493216]|[https://pubmed.ncbi.nlm.nih.gov/20044576 20044576]|[https://pubmed.ncbi.nlm.nih.gov/30643095 30643095]|[https://pubmed.ncbi.nlm.nih.gov/29732660 29732660]|[https://pubmed.ncbi.nlm.nih.gov/10580142 10580142]|[https://pubmed.ncbi.nlm.nih.gov/14568618 14568618]|[https://pubmed.ncbi.nlm.nih.gov/28079948 28079948]|[https://pubmed.ncbi.nlm.nih.gov/15467391 15467391]|[https://pubmed.ncbi.nlm.nih.gov/27812179 27812179]|[https://pubmed.ncbi.nlm.nih.gov/23761899 23761899]|[https://pubmed.ncbi.nlm.nih.gov/25737452 25737452]|[https://pubmed.ncbi.nlm.nih.gov/32930586 32930586]|[https://pubmed.ncbi.nlm.nih.gov/25381372 25381372]|[https://pubmed.ncbi.nlm.nih.gov/23434682 23434682]|[https://pubmed.ncbi.nlm.nih.gov/16857188 16857188]|[https://pubmed.ncbi.nlm.nih.gov/21452199 21452199]|[https://pubmed.ncbi.nlm.nih.gov/19429925 19429925]|[https://pubmed.ncbi.nlm.nih.gov/25361541 25361541]|[https://pubmed.ncbi.nlm.nih.gov/24297939 24297939]|[https://pubmed.ncbi.nlm.nih.gov/30322079 30322079]|[https://pubmed.ncbi.nlm.nih.gov/23428289 23428289]|[https://pubmed.ncbi.nlm.nih.gov/28427937 28427937]|[https://pubmed.ncbi.nlm.nih.gov/22746206 22746206]|[https://pubmed.ncbi.nlm.nih.gov/27533452 27533452]|[https://pubmed.ncbi.nlm.nih.gov/17502374 17502374]|[https://pubmed.ncbi.nlm.nih.gov/20816174 20816174]|[https://pubmed.ncbi.nlm.nih.gov/27496765 27496765] <br>
'''definition''' : O-linked glycans that are initiated by the addtion of a Man residue to Ser or Thr. Subsequent extension of the Man defines the O-Man core type, either M1, M2, or M3. The M1 type is initated by addition of a GlcNAc in β-linkage to the 2 position of the Man residue. M2 is initiated by addition of another GlcNAc to the 6 position of the M1 core. M3 is initiated by the addition of a GlcNAc in β-linkage to the 4 position of the Man residue. M1 and M2 type core glycans can be extended and branched with Gal, Fuc, Sialic Acid, and GlcA. The M3 core is uniquely extended by a multienzyme system to generate the matriglycan polysaccharide, a protein-specific modification found only on alpha-dystroglycan. [CHEBI:87761] <br>
'''term_xref''' : GlycoMotif:GGM.000055|GTC:G59126YU|CHEBI:87761|GlycoEpitope:EP0002|CID:[https://pubmed.ncbi.nlm.nih.gov/91859038 91859038]<br>
'''synonyms''' : O-mannosyl glycan <br>
'''function''' :  <br>
'''disease_associations''' : MEB/muscle-eye-brain disease[GlycoEpitope:EP0002]|WWS/walker-warburg syndrome |muscular dystrophy[GlycoEpitope:EP0002]|neuronal migration disorder[GlycoEpitope:EP0002]|Muscle-Eye-Brain disease (MEB) and Walker-Warburg Syndrome (WWS) have mutations in genes encoding glycosyltransferases needed for O -mannosyl oligosaccharide synthesis[GlycoEpitope:EP0002]|Muscular dystrophy and neuronal migration disorder are caused by mutations in a glycosyltransferase, POMGnT1.[GlycoEpitope:EP0002] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===P1 antigen===
[[File:G12460DL.png|thumb|G12460DL]]
'''term (main_entry)''' : P1 antigen <br>
'''glycan_dictionary_accession''' : GSD000141 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12460DL G12460DL] <br>
'''term_in_sentence''' : The P1 antigen was disovered in 1927 by Landsteiner and Levine, and Pk and NOR were described in 1951 and 1982, respectively.[PMID: [https://pubmed.ncbi.nlm.nih.gov/24046920 24046920]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29622537 29622537]|[https://pubmed.ncbi.nlm.nih.gov/26773500 26773500]|[https://pubmed.ncbi.nlm.nih.gov/24046920 24046920]|[https://pubmed.ncbi.nlm.nih.gov/6207232 6207232]|[https://pubmed.ncbi.nlm.nih.gov/8550516 8550516]|[https://pubmed.ncbi.nlm.nih.gov/6609976 6609976]|[https://pubmed.ncbi.nlm.nih.gov/6375319 6375319]|817855|[https://pubmed.ncbi.nlm.nih.gov/2428855 2428855]|[https://pubmed.ncbi.nlm.nih.gov/3312011 3312011]|[https://pubmed.ncbi.nlm.nih.gov/15364312 15364312]|[https://pubmed.ncbi.nlm.nih.gov/1937801 1937801]|[https://pubmed.ncbi.nlm.nih.gov/7729906 7729906] <br>
'''definition''' : An amino pentasaccharide consisting of α-D-galactose, β-D-galactose N-acetyl-α-D-glucosamine, β-D-galactose, and β-D-glucose residues joined in sequence with ((1→4)-, (1→4)-, (1→3)- and (1→4)-linkages, respectively.[CHEBI:68484] <br>
'''term_xref''' : GlycoMotif:GGM.000069|GTC:G12460DL|CID:[https://pubmed.ncbi.nlm.nih.gov/71296137 71296137]|CHEBI:68484|SugarBind_Ligand:160  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' : Shigellosis[SugarBind_Ligand:160] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453054/ Chapter 23]<br>
===Para-Forssman glycolipid===
[[File:G51699SI.png|thumb|G51699SI]]
'''term (main_entry)''' : Para-Forssman glycolipid <br>
'''glycan_dictionary_accession''' : GSD000142 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G51699SI G51699SI] <br>
'''term_in_sentence''' : A novel pentaglycosyl ceramide containing di-beta-N-acetylgalactos-aminyl residue (Para-Forssman glycolipid) isolated from human erythrocyte membrane. [PMID:[https://pubmed.ncbi.nlm.nih.gov/6814203 6814203]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6814203 6814203] <br>
'''definition''' : GalNAcβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1Cer [https://doi.org/10.1016/S0040-4039(01)93814-6<nowiki>] </nowiki><br>
'''term_xref''' : GlycoMotif:GGM.000085|GTC:G51699SI|CID:[https://pubmed.ncbi.nlm.nih.gov/56836111 56836111]|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565 <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' : Actinomycosis[SugarBind_Ligand:19] <br>
'''wikipedia''' : https://en.wikipedia.org/wiki/P1PK_blood_group_system <br>
'''essentials_of_glycobiology''' :  <br>
===Paragloboside===
[[File:G58896AZ.png|thumb|G58896AZ]]
'''term (main_entry)''' : Paragloboside <br>
'''glycan_dictionary_accession''' : GSD000143 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G58896AZ G58896AZ] <br>
'''term_in_sentence''' : Galactosyltransferase activities in sera of cancer patients were determined by assaying the formation of paragloboside from UDP-galactose and lactotriaosylceramide immobilized on microtiter plates by means of the enzyme-linked immunosorbent assay using a monoclonal antibody, H-11, directed to paragloboside. [PMID: [https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3345524 3345524]|850070|[https://pubmed.ncbi.nlm.nih.gov/10569746 10569746]|[https://pubmed.ncbi.nlm.nih.gov/30624951 30624951]|[https://pubmed.ncbi.nlm.nih.gov/29438961 29438961]|[https://pubmed.ncbi.nlm.nih.gov/6816790 6816790]|[https://pubmed.ncbi.nlm.nih.gov/1551117 1551117]|[https://pubmed.ncbi.nlm.nih.gov/6865961 6865961]|[https://pubmed.ncbi.nlm.nih.gov/25039255 25039255] <br>
'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is α.[CHEBI:65257] <br>
'''term_xref''' : GlycoMotif:GGM.000077|GTC:G58896AZ|CID:[https://pubmed.ncbi.nlm.nih.gov/21670519 21670519]|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' : Pharyngitis[SugarBind_Ligand:15]|Tracheobronchitis[SugarBind_Ligand:15]|Gonorrhea[SugarBind_Ligand:15]|Actinomycosis[SugarBind_Ligand:15]|Diarrhea[SugarBind_Ligand:15]|Hemorrhagic colitis[SugarBind_Ligand:15]|Chronic gastritis[SugarBind_Ligand:15]|Peptic ulcers[SugarBind_Ligand:15]|Gastric cancer[SugarBind_Ligand:15]|Influenza[SugarBind_Ligand:15] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
===Paucimannose===
'''term (main_entry)''' : Paucimannose <br>
'''glycan_dictionary_accession''' : GSD000144 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : The galactosylation of core fucose (GalFuc epitope) in paucimannose and complex-type N-glycans is characteristic of protostome organisms, including flatworms (planarians).[PMID:[https://pubmed.ncbi.nlm.nih.gov/29475940 29475940]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29475940 29475940]|[https://pubmed.ncbi.nlm.nih.gov/29803109 29803109]|[https://pubmed.ncbi.nlm.nih.gov/12603202 12603202]|[https://pubmed.ncbi.nlm.nih.gov/31817246 31817246]|[https://pubmed.ncbi.nlm.nih.gov/31719144 31719144]|[https://pubmed.ncbi.nlm.nih.gov/21057214 21057214]|[https://pubmed.ncbi.nlm.nih.gov/31932305 31932305]|[https://pubmed.ncbi.nlm.nih.gov/17132514 17132514]|[https://pubmed.ncbi.nlm.nih.gov/30382146 30382146]|[https://pubmed.ncbi.nlm.nih.gov/27731363 27731363]|[https://pubmed.ncbi.nlm.nih.gov/31325506 31325506]|[https://pubmed.ncbi.nlm.nih.gov/25746926 25746926]|[https://pubmed.ncbi.nlm.nih.gov/26513758 26513758]|[https://pubmed.ncbi.nlm.nih.gov/16522637 16522637]|[https://pubmed.ncbi.nlm.nih.gov/21169367 21169367]|[https://pubmed.ncbi.nlm.nih.gov/25190359 25190359]|[https://pubmed.ncbi.nlm.nih.gov/27928741 27928741]|[https://pubmed.ncbi.nlm.nih.gov/22496646 22496646]|[https://pubmed.ncbi.nlm.nih.gov/27384337 27384337]|[https://pubmed.ncbi.nlm.nih.gov/16897177 16897177]|[https://pubmed.ncbi.nlm.nih.gov/15228383 15228383]|[https://pubmed.ncbi.nlm.nih.gov/27379103 27379103]|[https://pubmed.ncbi.nlm.nih.gov/27189951 27189951]|[https://pubmed.ncbi.nlm.nih.gov/23475714 23475714]|[https://pubmed.ncbi.nlm.nih.gov/24907509 24907509]|[https://pubmed.ncbi.nlm.nih.gov/20558211 20558211]|[https://pubmed.ncbi.nlm.nih.gov/28060516 28060516]|[https://pubmed.ncbi.nlm.nih.gov/20441997 20441997]|[https://pubmed.ncbi.nlm.nih.gov/27720757 27720757]|[https://pubmed.ncbi.nlm.nih.gov/28817611 28817611]|[https://pubmed.ncbi.nlm.nih.gov/24550396 24550396]|[https://pubmed.ncbi.nlm.nih.gov/19494052 19494052]|[https://pubmed.ncbi.nlm.nih.gov/19515361 19515361]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28630087 28630087] [https://pubmed.ncbi.nlm.nih.gov/28630087 28630087]]|[https://pubmed.ncbi.nlm.nih.gov/31320997 31320997]|[https://pubmed.ncbi.nlm.nih.gov/30651366 30651366]|[https://pubmed.ncbi.nlm.nih.gov/30253927 30253927]|[https://pubmed.ncbi.nlm.nih.gov/25922361 25922361]|[https://pubmed.ncbi.nlm.nih.gov/31655162 31655162]|[https://pubmed.ncbi.nlm.nih.gov/18056652 18056652]|[https://pubmed.ncbi.nlm.nih.gov/24467287 24467287]|[https://pubmed.ncbi.nlm.nih.gov/32367383 32367383] <br>
'''definition''' : Any N-linked glycan derivative with composition Man1-4Fuc0-1 GlcNAc2, in which the chitobiose core (GlcNAc2) is intact. Found in relatively large amounts in invertebrates and plants, they are formed by removal of the non-reducing terminal GlcNAc (\added by GlcNAcT1) from GlcNAcMan3-5GlcNAc2 by a Golgi hexosaminidase and subsequent removal of Man residues by Golgi mannosidases. Pauscimannose glycans have also been detected in vertebrates.[CHEBI:144386] <br>
'''term_xref''' : CHEBI:144386 <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Polysialic acid===
'''term (main_entry)''' : Polysialic acid<br>
'''glycan_dictionary_accession''' : GSD000182<br>
'''glytoucan_accession ''' : <br>
'''term_in_sentence''' : Polysialic acid (PSA) is a carbohydrate composed of a linear polymer of α2,8-linked sialic acids, primarily attached to the Neural Cell Adhesion Molecule (NCAM). [PMID:36076963]<br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/36076963 36076963]|[https://pubmed.ncbi.nlm.nih.gov/35222358 35222358]<br>
'''definition''' : <br>
'''term_xref''' : GlycoMotif:GGM.000252<br>
'''synonyms''' :  polySia|PSA<br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : <br>
===Sd(A)/Cad===
[[File:G41052GC.png|thumb|G41052GC]]
'''term (main_entry)''' : Sd(A)/Cad <br>
'''glycan_dictionary_accession''' : GSD000145 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G41052GC G41052GC] <br>
'''term_in_sentence''' : The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24112972 24112972]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24112972 24112972]|[https://pubmed.ncbi.nlm.nih.gov/11577689 11577689]|[https://pubmed.ncbi.nlm.nih.gov/30067891 30067891]|[https://pubmed.ncbi.nlm.nih.gov/15361072 15361072] <br>
'''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, β-D-galactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the galactose residue of which is also linked (1→4) an N-acetyl-β-L-galactosamine residue.
[CHEBI:71561] <br>
'''term_xref''' : GlycoMotif:GGM.000051|GTC:G41052GC|CID:[https://pubmed.ncbi.nlm.nih.gov/70698375 70698375]|CHEBI:71561 <br>
'''synonyms''' : Sd^a /Cad <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453020/ Chapter 9] <br>
===SDlex===
[[File:G19619KS.png|thumb|G19619KS]]
'''term (main_entry)''' : SDlex <br>
'''glycan_dictionary_accession''' : GSD000146 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G19619KS G19619KS] <br>
'''term_in_sentence''' : Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure.[PMID: [https://pubmed.ncbi.nlm.nih.gov/3341453 3341453]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30226570 30226570]|[https://pubmed.ncbi.nlm.nih.gov/3341453 3341453]|[https://pubmed.ncbi.nlm.nih.gov/12725333 12725333] <br>
'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:148203] <br>
'''term_xref''' : GlycoMotif:GGM.000032|GTC:G19619KS|CID:[https://pubmed.ncbi.nlm.nih.gov/91856705 91856705]|CHEBI:148203  <br>
'''synonyms''' : Sdlex|SDLe^x|SDLex <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
===Seminolipid===
[[File:G72548RZ.png|thumb|G72548RZ]]
'''term (main_entry)''' : Seminolipid <br>
'''glycan_dictionary_accession''' : GSD000147 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72548RZ G72548RZ] <br>
'''term_in_sentence''' : A concise total synthesis of seminolipid, a sulfoglycolipid, has been achieved; key features include regioselective, tin-free sulfation of allyl β-d-galactopyranoside using 2,6-bis(trifluoromethyl)phenylboronic acid as protective reagent, stereoselective epoxidation, and site-selective acylation. [PMID: [https://pubmed.ncbi.nlm.nih.gov/31353379 31353379]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31353379 31353379]|[https://pubmed.ncbi.nlm.nih.gov/31736776 31736776]|[https://pubmed.ncbi.nlm.nih.gov/12810822 12810822]|[https://pubmed.ncbi.nlm.nih.gov/19582571 19582571]|[https://pubmed.ncbi.nlm.nih.gov/19542524 19542524]|[https://pubmed.ncbi.nlm.nih.gov/20670037 20670037]|[https://pubmed.ncbi.nlm.nih.gov/15659616 15659616]|[https://pubmed.ncbi.nlm.nih.gov/20817833 20817833]|870059|[https://pubmed.ncbi.nlm.nih.gov/10801776 10801776]|[https://pubmed.ncbi.nlm.nih.gov/21965315 21965315]|[https://pubmed.ncbi.nlm.nih.gov/8095813 8095813]|[https://pubmed.ncbi.nlm.nih.gov/1280685 1280685]|[https://pubmed.ncbi.nlm.nih.gov/4690236 4690236]|[https://pubmed.ncbi.nlm.nih.gov/34199863 34199863]|[https://pubmed.ncbi.nlm.nih.gov/4207869 4207869]|[https://pubmed.ncbi.nlm.nih.gov/2373957 2373957]|845131 <br>
'''definition''' :  <br>
'''term_xref''' : GlycoMotif:GGM.000062|GTC:G72548RZ<br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453042/ Chapter 14]<br>
===Sialopentaosylceramide===
[[File:G13224CR.png|thumb|G13224CR]]
'''term (main_entry)''' : Sialopentaosylceramide <br>
'''glycan_dictionary_accession''' : GSD000148 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G13224CR G13224CR] <br>
'''term_in_sentence''' : Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosap[PMID: [https://pubmed.ncbi.nlm.nih.gov/2139874 2139874]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2139874 2139874] <br>
'''definition''' : A ganglioside in which the oligosaccharide portion is composed of a pentasaccharide containing one or more sialic acid residues.[CHEBI:36542] <br>
'''term_xref''' : GlycoMotif:GGM.000097|GTC:G13224CR|CID:[https://pubmed.ncbi.nlm.nih.gov/91859576 91859576]|CHEBI:148045|KEGG:G00883|CHEBI:36542 <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Sialosyl paragloboside===
[[File:G50123ZO.png|thumb|G50123ZO]]
'''term (main_entry)''' : Sialosyl paragloboside <br>
'''glycan_dictionary_accession''' : GSD000149 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G50123ZO G50123ZO] <br>
'''term_in_sentence''' : Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG).[PMID:[https://pubmed.ncbi.nlm.nih.gov/8862128 8862128]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/8862128 8862128]|[https://pubmed.ncbi.nlm.nih.gov/7236652 7236652]|[https://pubmed.ncbi.nlm.nih.gov/2370108 2370108]|[https://pubmed.ncbi.nlm.nih.gov/3133978 3133978]|[https://pubmed.ncbi.nlm.nih.gov/2905604 2905604]|[https://pubmed.ncbi.nlm.nih.gov/1749114 1749114]|[https://pubmed.ncbi.nlm.nih.gov/1573418 1573418] <br>
'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-D-GlcpNAc with β configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.[CHEBI:71612] <br>
'''term_xref''' : GlycoMotif:GGM.000081|GTC:G50123ZO|CID:[https://pubmed.ncbi.nlm.nih.gov/91845504 91845504]|KEGG:G01429|CHEBI:151914  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Sialyl Lewis a===
[[File:G00053MO.png|thumb|G00053MO]]
'''term (main_entry)''' : Sialyl Lewis a <br>
'''glycan_dictionary_accession''' : GSD000150 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00053MO G00053MO] <br>
'''term_in_sentence''' : By comparing the serum O-glycan profiles from healthy controls with those of cancer patients, we identified a marker candidate, core 1 sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal) (abbreviated C1SLA), whose concentration appeared to be weakly correlated with CA19-9 values.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888] [https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888] [https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]]|[https://pubmed.ncbi.nlm.nih.gov/31424423 31424423]|[https://pubmed.ncbi.nlm.nih.gov/26530370 26530370]|[https://pubmed.ncbi.nlm.nih.gov/17760270 17760270]|[https://pubmed.ncbi.nlm.nih.gov/18343410 18343410]|[https://pubmed.ncbi.nlm.nih.gov/16033091 16033091]|[https://pubmed.ncbi.nlm.nih.gov/8829184 8829184]|[https://pubmed.ncbi.nlm.nih.gov/11907351 11907351]|[https://pubmed.ncbi.nlm.nih.gov/20592391 20592391]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888] [https://pubmed.ncbi.nlm.nih.gov/26641888 26641888]]|[https://pubmed.ncbi.nlm.nih.gov/24128856 24128856]|[https://pubmed.ncbi.nlm.nih.gov/30249386 30249386]|[https://pubmed.ncbi.nlm.nih.gov/10773785 10773785]|[https://pubmed.ncbi.nlm.nih.gov/16149606 16149606]|[https://pubmed.ncbi.nlm.nih.gov/10996727 10996727]|[https://pubmed.ncbi.nlm.nih.gov/10436809 10436809]|[https://pubmed.ncbi.nlm.nih.gov/10667238 10667238]|[https://pubmed.ncbi.nlm.nih.gov/7720892 7720892]|[https://pubmed.ncbi.nlm.nih.gov/7630017 7630017]|[https://pubmed.ncbi.nlm.nih.gov/10612415 10612415]|[https://pubmed.ncbi.nlm.nih.gov/9836451 9836451]|[https://pubmed.ncbi.nlm.nih.gov/12511721 12511721]|[https://pubmed.ncbi.nlm.nih.gov/22623153 22623153] <br>
'''definition''' : A sialyated version of Lewis A with a branched structure of amino tetrasaccharide consisting of a sialyl residue, linked (2→3) to a galactosyl residue that in turn is linked (1→3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.[CHEBI:62681] <br>
'''term_xref''' : GTC:G00053MO|GlycoEpitope:EP0008|CID:[https://pubmed.ncbi.nlm.nih.gov/53356732 53356732]|CHEBI:62681|GlycoMotif:GGM.000024<br>
'''synonyms''' : SLea|CA19-9|CA19-9 antigen|SLe^a|Slea <br>
'''function''' : The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0008] <br>
'''disease_associations''' : pancreatic adenocarcinoma[GlycoEpitope:EP0008]|hepatocellular cancer[GlycoEpitope:EP0008]|cholangiocellular cancer[GlycoEpitope:EP0008]|gastric cancer|[GlycoEpitope:EP0008]colorectal cancer[GlycoEpitope:EP0008]|ovarian cancer[GlycoEpitope:EP0008]|lung cancer[GlycoEpitope:EP0008]|breast cancer[GlycoEpitope:EP0008]|uterine cancer[GlycoEpitope:EP0008] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Sialyl Lewis x===
[[File:G00054MO.png|thumb|G00054MO]]
'''term (main_entry)''' : Sialyl Lewis x <br>
'''glycan_dictionary_accession''' : GSD000151 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00054MO G00054MO] <br>
'''term_in_sentence''' : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12828079 12828079]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172] [https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]]|[https://pubmed.ncbi.nlm.nih.gov/10075923 10075923]|[https://pubmed.ncbi.nlm.nih.gov/19054801 19054801]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9642161 9642161] [https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]]|[https://pubmed.ncbi.nlm.nih.gov/31054033 31054033]|[https://pubmed.ncbi.nlm.nih.gov/15229399 15229399]|[https://pubmed.ncbi.nlm.nih.gov/29061785 29061785]|[https://pubmed.ncbi.nlm.nih.gov/16033070 16033070]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172] [https://pubmed.ncbi.nlm.nih.gov/8940172 8940172]]|[https://pubmed.ncbi.nlm.nih.gov/9298692 9298692]|[https://pubmed.ncbi.nlm.nih.gov/18607721 18607721]|[https://pubmed.ncbi.nlm.nih.gov/22593503 22593503]|[https://pubmed.ncbi.nlm.nih.gov/25944902 25944902]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9642161 9642161] [https://pubmed.ncbi.nlm.nih.gov/9642161 9642161]]|[https://pubmed.ncbi.nlm.nih.gov/15780091 15780091]|[https://pubmed.ncbi.nlm.nih.gov/20401888 20401888] <br>
'''definition''' : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2030970 2030970] [https://pubmed.ncbi.nlm.nih.gov/2030970 2030970]],CHEI:71622] <br>
'''term_xref''' : GTC:G00054MO |GlycoEpitope:EP0012|CID:[https://pubmed.ncbi.nlm.nih.gov/44456859 44456859]|CHEBI:71622|MESH:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2030970 2030970] [https://pubmed.ncbi.nlm.nih.gov/2030970 2030970]]|GlycoMotif:GGM.000022 <br>
'''synonyms''' : SLe(x)|SLe^x|SLex|Slex <br>
'''function''' : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012] <br>
'''disease_associations''' : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Sialyl Lewis x-i===
[[File:G06597DS.png|thumb|G06597DS]]
'''term (main_entry)''' : Sialyl Lewis x-i <br>
'''glycan_dictionary_accession''' : GSD000152 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G06597DS G06597DS] <br>
'''term_in_sentence''' : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:[https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9815711 9815711]|[https://pubmed.ncbi.nlm.nih.gov/9730796 9730796]|[https://pubmed.ncbi.nlm.nih.gov/11867833 11867833]|[https://pubmed.ncbi.nlm.nih.gov/9713476 9713476]|[https://pubmed.ncbi.nlm.nih.gov/2819663 2819663]|[https://pubmed.ncbi.nlm.nih.gov/9372327 9372327]|[https://pubmed.ncbi.nlm.nih.gov/9615762 9615762]|[https://pubmed.ncbi.nlm.nih.gov/1352835 1352835]|[https://pubmed.ncbi.nlm.nih.gov/2575680 2575680]|[https://pubmed.ncbi.nlm.nih.gov/9330526 9330526]|[https://pubmed.ncbi.nlm.nih.gov/8753037 8753037]|[https://pubmed.ncbi.nlm.nih.gov/2210805 2210805]|[https://pubmed.ncbi.nlm.nih.gov/12680155 12680155]|[https://pubmed.ncbi.nlm.nih.gov/11974864 11974864]|[https://pubmed.ncbi.nlm.nih.gov/10453898 10453898]|[https://pubmed.ncbi.nlm.nih.gov/2565704 2565704]|[https://pubmed.ncbi.nlm.nih.gov/17144590 17144590] <br>
'''definition''' :  <br>
'''term_xref''' : GTC:G06597DS|GlycoEpitope:EP0043|CID:[https://pubmed.ncbi.nlm.nih.gov/91855346 91855346]|CHEBI:147019 <br>
'''synonyms''' :  <br>
'''function''' : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043] <br>
'''disease_associations''' : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Sialyl T antigen===
[[File:G65562ZE.png|thumb|G65562ZE]]
'''term (main_entry)''' : Sialyl T antigen <br>
'''glycan_dictionary_accession''' : GSD000153 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G65562ZE G65562ZE] <br>
'''term_in_sentence''' : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32583304 32583304]|[https://pubmed.ncbi.nlm.nih.gov/31897478 31897478]|[https://pubmed.ncbi.nlm.nih.gov/31719620 31719620]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10365852 10365852] [https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]]|[https://pubmed.ncbi.nlm.nih.gov/25727149 25727149]|[https://pubmed.ncbi.nlm.nih.gov/11523928 11523928]|[https://pubmed.ncbi.nlm.nih.gov/20407596 20407596]|[https://pubmed.ncbi.nlm.nih.gov/25464017 25464017]|[https://pubmed.ncbi.nlm.nih.gov/30864133 30864133]|[https://pubmed.ncbi.nlm.nih.gov/26391208 26391208]|[https://pubmed.ncbi.nlm.nih.gov/19811634 19811634]|[https://pubmed.ncbi.nlm.nih.gov/29796594 29796594]|[https://pubmed.ncbi.nlm.nih.gov/23725156 23725156]|[https://pubmed.ncbi.nlm.nih.gov/8905873 8905873]|[https://pubmed.ncbi.nlm.nih.gov/11192238 11192238]|[https://pubmed.ncbi.nlm.nih.gov/18275089 18275089]|[https://pubmed.ncbi.nlm.nih.gov/27037304 27037304]|[https://pubmed.ncbi.nlm.nih.gov/11949946 11949946]|[https://pubmed.ncbi.nlm.nih.gov/15604091 15604091]|[https://pubmed.ncbi.nlm.nih.gov/24118321 24118321] <br>
'''definition''' : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257] <br>
'''term_xref''' : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:[https://pubmed.ncbi.nlm.nih.gov/44611726 44611726]|CHEBI:65257  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Sialylated biantennary===
'''term (main_entry)''' : Sialylated biantennary <br>
'''glycan_dictionary_accession''' : GSD000154 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]|[https://pubmed.ncbi.nlm.nih.gov/31510952 31510952]|[https://pubmed.ncbi.nlm.nih.gov/29265394 29265394]|[https://pubmed.ncbi.nlm.nih.gov/31589880 31589880]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/26045275 26045275]|[https://pubmed.ncbi.nlm.nih.gov/29029079 29029079]|[https://pubmed.ncbi.nlm.nih.gov/30252064 30252064] <br>
'''definition''' : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN] <br>
'''term_xref''' :  <br>
'''synonyms''' : sialyl biantennary <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Sialylated complex-type===
'''term (main_entry)''' : Sialylated complex-type <br>
'''glycan_dictionary_accession''' : GSD000155 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1694115 1694115]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1694115 1694115]|[https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]|[https://pubmed.ncbi.nlm.nih.gov/30471292 30471292]|[https://pubmed.ncbi.nlm.nih.gov/30969765 30969765]|[https://pubmed.ncbi.nlm.nih.gov/11058758 11058758]|[https://pubmed.ncbi.nlm.nih.gov/28342150 28342150] <br>
'''definition''' : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues. <br>
'''term_xref''' :  <br>
'''synonyms''' : sialo-complex type <br>
'''function''' : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: [https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]] Appears in IgG-Fc.[PMID:[https://pubmed.ncbi.nlm.nih.gov/20647032 20647032] ] <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
===Sialylated LacdiNAc===
[[File:G55583HW.png|thumb|G55583HW]]
'''term (main_entry)''' : Sialylated LacdiNAc<br>
'''glycan_dictionary_accession''' : GSD000192<br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G55583HW G55583HW] <br>
'''term_in_sentence''' :  The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewisx), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewisx).[PMID:7592613]<br>
'''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/7592613 7592613]|[https://pubmed.ncbi.nlm.nih.gov/34192302 34192302]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/16286643 16286643]<br>
'''definition''' :  <br>
'''term_xref''' : GlycoMotif:GGM.000050<br>
'''synonyms''' :  sialylated-LacdiNAc|Sialylated LDN<br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Sialylated tetraantennary===
'''term (main_entry)''' : Sialylated tetraantennary <br>
'''glycan_dictionary_accession''' : GSD000156 <br>
'''glytoucan_accession ''' :  <br>
'''term_in_sentence''' : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16321355 16321355]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865] <br>
'''definition''' : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues. <br>
'''term_xref''' :  <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===Sialyl-Tn antigen===
[[File:G36123IU.png|thumb|G36123IU]]
'''term (main_entry)''' : Sialyl-Tn antigen <br>
'''glycan_dictionary_accession''' : GSD000157 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G36123IU G36123IU] <br>
'''term_in_sentence''' : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:[https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23035012 23035012]|[https://pubmed.ncbi.nlm.nih.gov/29273237 29273237]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/31595388 31595388]|[https://pubmed.ncbi.nlm.nih.gov/26617889 26617889]|[https://pubmed.ncbi.nlm.nih.gov/1720922 1720922]|[https://pubmed.ncbi.nlm.nih.gov/15466199 15466199]|[https://pubmed.ncbi.nlm.nih.gov/10971172 10971172]|[https://pubmed.ncbi.nlm.nih.gov/14652017 14652017]|[https://pubmed.ncbi.nlm.nih.gov/8616877 8616877]|[https://pubmed.ncbi.nlm.nih.gov/1543361 1543361]|[https://pubmed.ncbi.nlm.nih.gov/16965854 16965854]|[https://pubmed.ncbi.nlm.nih.gov/21566901 21566901]|[https://pubmed.ncbi.nlm.nih.gov/9269833 9269833]|[https://pubmed.ncbi.nlm.nih.gov/9834267 9834267]|[https://pubmed.ncbi.nlm.nih.gov/24970145 24970145]|[https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/30018351 30018351]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]|[https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/28632300 28632300]|[https://pubmed.ncbi.nlm.nih.gov/11308020 11308020]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10365852 10365852] [https://pubmed.ncbi.nlm.nih.gov/10365852 10365852]]|[https://pubmed.ncbi.nlm.nih.gov/17195456 17195456]|[https://pubmed.ncbi.nlm.nih.gov/23567325 23567325]|[https://pubmed.ncbi.nlm.nih.gov/11014575 11014575]|[https://pubmed.ncbi.nlm.nih.gov/2342728 2342728]|[https://pubmed.ncbi.nlm.nih.gov/8575847 8575847]|[https://pubmed.ncbi.nlm.nih.gov/1851822 1851822]|[https://pubmed.ncbi.nlm.nih.gov/11735169 11735169]|[https://pubmed.ncbi.nlm.nih.gov/20960853 20960853]|[https://pubmed.ncbi.nlm.nih.gov/7846011 7846011] <br>
'''definition''' : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818] <br>
'''term_xref''' : GTC:G36123IU|GlycoEpitope:EP0022|CID:[https://pubmed.ncbi.nlm.nih.gov/51351800 51351800]|CHEBI:61818 <br>
'''synonyms''' :  <br>
'''function''' : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022] <br>
'''disease_associations''' : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453027/ Chapter 56]<br>
===SLex Core 2 O-glycan===
'''term (main_entry)''' : SLex Core 2 O-glycan <br>
'''glycan_dictionary_accession''' : GSD000158 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97345NY G97345NY] <br>
'''term_in_sentence''' : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:[https://pubmed.ncbi.nlm.nih.gov/15596301 15596301]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15596301 15596301] <br>
'''definition''' :  <br>
'''term_xref''' : GlycoMotif:GGM.000053|GTC:G97345NY <br>
'''synonyms''' : SLe^x Core 2 O-glycan <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===SSEA-1===
[[File:G85497PI.png|thumb|G85497PI]]
'''term (main_entry)''' : SSEA-1 <br>
'''glycan_dictionary_accession''' : GSD000159 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G85497PI G85497PI] <br>
'''term_in_sentence''' : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27550342 27550342]|[https://pubmed.ncbi.nlm.nih.gov/25564944 25564944]|[https://pubmed.ncbi.nlm.nih.gov/30987116 30987116]|[https://pubmed.ncbi.nlm.nih.gov/10778174 10778174]|[https://pubmed.ncbi.nlm.nih.gov/19427293 19427293]|[https://pubmed.ncbi.nlm.nih.gov/24923741 24923741]|[https://pubmed.ncbi.nlm.nih.gov/28092949 28092949]|[https://pubmed.ncbi.nlm.nih.gov/16499901 16499901]|[https://pubmed.ncbi.nlm.nih.gov/10470652 10470652]|[https://pubmed.ncbi.nlm.nih.gov/18787210 18787210]|[https://pubmed.ncbi.nlm.nih.gov/2885312 2885312]|[https://pubmed.ncbi.nlm.nih.gov/16149609 16149609]|[https://pubmed.ncbi.nlm.nih.gov/17003364 17003364]|[https://pubmed.ncbi.nlm.nih.gov/27363517 27363517]|[https://pubmed.ncbi.nlm.nih.gov/15505339 15505339]|[https://pubmed.ncbi.nlm.nih.gov/27990704 27990704]|[https://pubmed.ncbi.nlm.nih.gov/2568298 2568298]|[https://pubmed.ncbi.nlm.nih.gov/20491542 20491542]|[https://pubmed.ncbi.nlm.nih.gov/23572256 23572256]|[https://pubmed.ncbi.nlm.nih.gov/1977666 1977666]|[https://pubmed.ncbi.nlm.nih.gov/9553168 9553168]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/20458727 20458727] [https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]]|[https://pubmed.ncbi.nlm.nih.gov/2566639 2566639]|[https://pubmed.ncbi.nlm.nih.gov/14577357 14577357]|[https://pubmed.ncbi.nlm.nih.gov/20960856 20960856]|[https://pubmed.ncbi.nlm.nih.gov/15547746 15547746]|[https://pubmed.ncbi.nlm.nih.gov/9096265 9096265]|[https://pubmed.ncbi.nlm.nih.gov/30639212 30639212]|[https://pubmed.ncbi.nlm.nih.gov/1357195 1357195]|[https://pubmed.ncbi.nlm.nih.gov/1359630 1359630]|[https://pubmed.ncbi.nlm.nih.gov/20181261 20181261]|[https://pubmed.ncbi.nlm.nih.gov/20508065 20508065]|[https://pubmed.ncbi.nlm.nih.gov/2907526 2907526]|[https://pubmed.ncbi.nlm.nih.gov/22624699 22624699]|[https://pubmed.ncbi.nlm.nih.gov/22988836 22988836]|[https://pubmed.ncbi.nlm.nih.gov/17183690 17183690]|[https://pubmed.ncbi.nlm.nih.gov/27188587 27188587]|[https://pubmed.ncbi.nlm.nih.gov/7908065 7908065]|[https://pubmed.ncbi.nlm.nih.gov/10400391 10400391]|[https://pubmed.ncbi.nlm.nih.gov/6137429 6137429]|[https://pubmed.ncbi.nlm.nih.gov/1979260 1979260]|[https://pubmed.ncbi.nlm.nih.gov/2898921 2898921]|[https://pubmed.ncbi.nlm.nih.gov/14736812 14736812]|[https://pubmed.ncbi.nlm.nih.gov/30919971 30919971] <br>
'''definition''' :  <br>
'''term_xref''' : GTC:G85497PI |GlycoEpitope:EP0042|CID:[https://pubmed.ncbi.nlm.nih.gov/91851144 91851144]|CHEBI:154343  <br>
'''synonyms''' :  <br>
'''function''' : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042] <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453030/ Chapter 10]<br>
===SSEA-3===
[[File:G25129BT.png|thumb|G25129BT]]
'''term (main_entry)''' : SSEA-3 <br>
'''glycan_dictionary_accession''' : GSD000160 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25129BT G25129BT] <br>
'''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926] [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926] [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]]|[https://pubmed.ncbi.nlm.nih.gov/30271856 30271856]|[https://pubmed.ncbi.nlm.nih.gov/32684574 32684574]|[https://pubmed.ncbi.nlm.nih.gov/26677875 26677875]|[https://pubmed.ncbi.nlm.nih.gov/23175153 23175153]|[https://pubmed.ncbi.nlm.nih.gov/32525407 32525407]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29227830 29227830] [https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18773292 18773292] [https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]]|[https://pubmed.ncbi.nlm.nih.gov/25561682 25561682]|[https://pubmed.ncbi.nlm.nih.gov/10837462 10837462]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2412924 2412924] [https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/21149348 21149348] [https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/17008424 17008424] [https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2874662 2874662] [https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543] [https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]]|[https://pubmed.ncbi.nlm.nih.gov/31304790 31304790]|[https://pubmed.ncbi.nlm.nih.gov/31642560 31642560]|[https://pubmed.ncbi.nlm.nih.gov/30484221 30484221]|[https://pubmed.ncbi.nlm.nih.gov/30525067 30525067]|[https://pubmed.ncbi.nlm.nih.gov/21161592 21161592]|[https://pubmed.ncbi.nlm.nih.gov/27325407 27325407]|[https://pubmed.ncbi.nlm.nih.gov/28170296 28170296]|[https://pubmed.ncbi.nlm.nih.gov/29637816 29637816]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/27318475 27318475] [https://pubmed.ncbi.nlm.nih.gov/27318475 27318475]]|[https://pubmed.ncbi.nlm.nih.gov/31346146 31346146]|[https://pubmed.ncbi.nlm.nih.gov/7648586 7648586]|[https://pubmed.ncbi.nlm.nih.gov/24236059 24236059]|[https://pubmed.ncbi.nlm.nih.gov/21964054 21964054]|[https://pubmed.ncbi.nlm.nih.gov/27456773 27456773]|[https://pubmed.ncbi.nlm.nih.gov/30558911 30558911]|[https://pubmed.ncbi.nlm.nih.gov/21559451 21559451]|[https://pubmed.ncbi.nlm.nih.gov/29312455 29312455]|[https://pubmed.ncbi.nlm.nih.gov/27549315 27549315]|[https://pubmed.ncbi.nlm.nih.gov/30599359 30599359]|[https://pubmed.ncbi.nlm.nih.gov/6141938 6141938]|[https://pubmed.ncbi.nlm.nih.gov/28883415 28883415]|[https://pubmed.ncbi.nlm.nih.gov/30733757 30733757]|[https://pubmed.ncbi.nlm.nih.gov/26041528 26041528]|[https://pubmed.ncbi.nlm.nih.gov/16643871 16643871] <br>
'''definition''' : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071] <br>
'''term_xref''' : GTC:G25129BT|GlycoEpitope:EP0039|CID:[https://pubmed.ncbi.nlm.nih.gov/91855781 91855781]|CHEBI:149071|GlycoMotif:GGM.000079 <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :  <br>
===SSEA-4===
[[File:G84263XI.png|thumb|G84263XI]]
'''term (main_entry)''' : SSEA-4 <br>
'''glycan_dictionary_accession''' : GSD000161 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G84263XI G84263XI] <br>
'''term_in_sentence''' : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926] [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27845370 27845370]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926] [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926]]|[https://pubmed.ncbi.nlm.nih.gov/26295543 26295543]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543] [https://pubmed.ncbi.nlm.nih.gov/25171543 25171543]]|[https://pubmed.ncbi.nlm.nih.gov/25978997 25978997]|[https://pubmed.ncbi.nlm.nih.gov/30296654 30296654]|[https://pubmed.ncbi.nlm.nih.gov/25853231 25853231]|[https://pubmed.ncbi.nlm.nih.gov/24862940 24862940]|[https://pubmed.ncbi.nlm.nih.gov/31243630 31243630]|[https://pubmed.ncbi.nlm.nih.gov/28736232 28736232]|[https://pubmed.ncbi.nlm.nih.gov/22895512 22895512]|[https://pubmed.ncbi.nlm.nih.gov/24578244 24578244]|[https://pubmed.ncbi.nlm.nih.gov/29478902 29478902]|[https://pubmed.ncbi.nlm.nih.gov/23574147 23574147]|[https://pubmed.ncbi.nlm.nih.gov/23768762 23768762]|[https://pubmed.ncbi.nlm.nih.gov/27797400 27797400]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/29227830 29227830] [https://pubmed.ncbi.nlm.nih.gov/29227830 29227830]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18773292 18773292] [https://pubmed.ncbi.nlm.nih.gov/18773292 18773292]]|[https://pubmed.ncbi.nlm.nih.gov/25123923 25123923]|[https://pubmed.ncbi.nlm.nih.gov/22924692 22924692]|[https://pubmed.ncbi.nlm.nih.gov/22665977 22665977]|[https://pubmed.ncbi.nlm.nih.gov/23330736 23330736]|[https://pubmed.ncbi.nlm.nih.gov/31831622 31831622]|[https://pubmed.ncbi.nlm.nih.gov/31916611 31916611]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2412924 2412924] [https://pubmed.ncbi.nlm.nih.gov/2412924 2412924]]|[https://pubmed.ncbi.nlm.nih.gov/16033656 16033656]|[https://pubmed.ncbi.nlm.nih.gov/24866102 24866102]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/20458727 20458727] [https://pubmed.ncbi.nlm.nih.gov/20458727 20458727]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/21149348 21149348] [https://pubmed.ncbi.nlm.nih.gov/21149348 21149348]]|[https://pubmed.ncbi.nlm.nih.gov/26940129 26940129]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/17008424 17008424] [https://pubmed.ncbi.nlm.nih.gov/17008424 17008424]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2874662 2874662] [https://pubmed.ncbi.nlm.nih.gov/2874662 2874662]]|[https://pubmed.ncbi.nlm.nih.gov/23301556 23301556]|[https://pubmed.ncbi.nlm.nih.gov/27836003 27836003]|[https://pubmed.ncbi.nlm.nih.gov/19118716 19118716]|[https://pubmed.ncbi.nlm.nih.gov/24550271 24550271]|[https://pubmed.ncbi.nlm.nih.gov/32988880 32988880]|[https://pubmed.ncbi.nlm.nih.gov/22743677 22743677]|[https://pubmed.ncbi.nlm.nih.gov/20683402 20683402]|[https://pubmed.ncbi.nlm.nih.gov/17062733 17062733]|[https://pubmed.ncbi.nlm.nih.gov/23570331 23570331]|[https://pubmed.ncbi.nlm.nih.gov/30310530 30310530]|[https://pubmed.ncbi.nlm.nih.gov/31545316 31545316]|[https://pubmed.ncbi.nlm.nih.gov/23509763 23509763]|[https://pubmed.ncbi.nlm.nih.gov/24364909 24364909]|[https://pubmed.ncbi.nlm.nih.gov/18273440 18273440]|[https://pubmed.ncbi.nlm.nih.gov/28985528 28985528]|[https://pubmed.ncbi.nlm.nih.gov/22266579 22266579] <br>
'''definition''' :  <br>
'''term_xref''' : GTC:G84263XI|GlycoEpitope:EP0044|CID:[https://pubmed.ncbi.nlm.nih.gov/91845478 91845478]|CHEBI:154843 <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' : teratocarcinoma[GlycoEpitope:EP0044] <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47] <br>
===Sulfated LacdiNAc===
[[File:G18464VS.png|thumb|G18464VS]]
'''term (main_entry)''' : Sulfated LacdiNAc<br>
'''glycan_dictionary_accession''' : GSD000191<br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18464VS G18464VS] <br>
'''term_in_sentence''' :  The mRNA expression of the enzymes related to the formation of sulfated LacdiNAc:β(1,4)-N-acetylgalactosaminyltransferases 3 (B4GALNT3) and 4 (B4GALNT4), carbohydrate sulfotransferases 8 (CHST8) and 9 (CHST9); and β(1,4)-galactosyltransferase 1 (B4GALT1) in these cells was confirmed by RT-PCR (Fig. S4).[PMID:31558607]<br>
'''publication''' :  [https://pubmed.ncbi.nlm.nih.gov/31558607 31558607]|[https://pubmed.ncbi.nlm.nih.gov/27318476 27318476]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/11279168 11279168]|[https://pubmed.ncbi.nlm.nih.gov/26688390 26688390]<br>
'''definition''' :  <br>
'''term_xref''' : GlycoMotif:GGM.000049<br>
'''synonyms''' :  4'-O-sulfated LacdiNAc|4'-sulfated LDN|sulfated LDN<br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' :
===Sulfatide===
'''term (main_entry)''' : Sulfatide <br>
'''glycan_dictionary_accession''' : GSD000162 <br>
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G72548RZ G72548RZ] <br>
'''term_in_sentence''' : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23550344 23550344]] <br>
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23550344 23550344]|[https://pubmed.ncbi.nlm.nih.gov/18465098 18465098]|[https://pubmed.ncbi.nlm.nih.gov/26542149 26542149]|[https://pubmed.ncbi.nlm.nih.gov/15158666 15158666]|[https://pubmed.ncbi.nlm.nih.gov/10434709 10434709]|[https://pubmed.ncbi.nlm.nih.gov/22619219 22619219]|[https://pubmed.ncbi.nlm.nih.gov/29676479 29676479]|[https://pubmed.ncbi.nlm.nih.gov/30196830 30196830]|[https://pubmed.ncbi.nlm.nih.gov/16143863 16143863]|[https://pubmed.ncbi.nlm.nih.gov/1052451 1052451]|[https://pubmed.ncbi.nlm.nih.gov/30400820 30400820]|[https://pubmed.ncbi.nlm.nih.gov/29887538 29887538]|[https://pubmed.ncbi.nlm.nih.gov/26981544 26981544]|[https://pubmed.ncbi.nlm.nih.gov/17986152 17986152]|[https://pubmed.ncbi.nlm.nih.gov/31739035 31739035]|[https://pubmed.ncbi.nlm.nih.gov/19941861 19941861]|[https://pubmed.ncbi.nlm.nih.gov/24578319 24578319]|[https://pubmed.ncbi.nlm.nih.gov/30531843 30531843]|[https://pubmed.ncbi.nlm.nih.gov/25645724 25645724]|[https://pubmed.ncbi.nlm.nih.gov/31197846 31197846]|[https://pubmed.ncbi.nlm.nih.gov/22821828 22821828]|[https://pubmed.ncbi.nlm.nih.gov/27861899 27861899]|[https://pubmed.ncbi.nlm.nih.gov/31037952 31037952]|[https://pubmed.ncbi.nlm.nih.gov/23593400 23593400]|[https://pubmed.ncbi.nlm.nih.gov/23604989 23604989]|[https://pubmed.ncbi.nlm.nih.gov/17855742 17855742]|[https://pubmed.ncbi.nlm.nih.gov/25966258 25966258]|[https://pubmed.ncbi.nlm.nih.gov/25989600 25989600]|[https://pubmed.ncbi.nlm.nih.gov/9657940 9657940]|[https://pubmed.ncbi.nlm.nih.gov/29497057 29497057]|[https://pubmed.ncbi.nlm.nih.gov/12838515 12838515]|[https://pubmed.ncbi.nlm.nih.gov/25170267 25170267]|[https://pubmed.ncbi.nlm.nih.gov/9878314 9878314]|[https://pubmed.ncbi.nlm.nih.gov/20554435 20554435]|[https://pubmed.ncbi.nlm.nih.gov/1410493 1410493]|[https://pubmed.ncbi.nlm.nih.gov/26585924 26585924]|[https://pubmed.ncbi.nlm.nih.gov/17257892 17257892]|[https://pubmed.ncbi.nlm.nih.gov/17044925 17044925]|[https://pubmed.ncbi.nlm.nih.gov/21089387 21089387]|[https://pubmed.ncbi.nlm.nih.gov/11445552 11445552]|[https://pubmed.ncbi.nlm.nih.gov/22977233 22977233]|[https://pubmed.ncbi.nlm.nih.gov/21437360 21437360]|[https://pubmed.ncbi.nlm.nih.gov/17179664 17179664]|[https://pubmed.ncbi.nlm.nih.gov/6273571 6273571]|[https://pubmed.ncbi.nlm.nih.gov/8370675 8370675] <br>
'''definition''' :  <br>
'''term_xref''' : GlycoMotif:GGM.000063|GTC:G72548RZ <br>
'''synonyms''' :  <br>
'''function''' :  <br>
'''disease_associations''' :  <br>
'''wikipedia''' :  <br>
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453023/ Chapter 47]<br>

Revision as of 20:13, 7 April 2023

Monosialylated

term (main_entry) : Monosialylated 
glycan_dictionary_accession : GSD000123
glytoucan_accession  :
term_in_sentence : The structures of the asparagine-linked sugar chains of U- CD59 were biantennary complex type , only 4.2% of which are monosialylated.[PMID:7514386]
publication : 7514386|8477709|8942648|29752599|31669586|29747818|16425369|12089170|31390883|1632647|29733234|31110965|31566965|30555678|28263871|29652662|25915761|16381065|29247593|28370937|23896595|26633899|32155999|25261856|2737211|26945091|27065039|26784838|26582205
definition : A glycan that have the addition of one sialic acid residues.
term_xref :
synonyms :
function : appears in bovine brain gangliosides.[PMID: 29752599]
disease_associations :
wikipedia :
essentials_of_glycobiology :


Monosialyl-biantennary

term (main_entry) : Monosialyl-biantennary 
glycan_dictionary_accession : GSD000124
glytoucan_accession  :
term_in_sentence : In contrast, the sugar chain structure of HCC highly specific AFP isoform was found to comprise a monosialyl-biantennary sugar chain with additional fucosylation of the proximal N-acetylglucosamine.[PMID:7686446]
publication : 7686446|1374031|9648261|10460833|19524219|10207016|15797573|15218190
definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of one sialic acid residues.
term_xref :
synonyms : monosialyl biantennary|sialylated diantennary|sialylated biantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Monosialyl-Gb5

G32254QI
term (main_entry) : Monosialyl-Gb5 
glycan_dictionary_accession : GSD000125
glytoucan_accession  : G32254QI
term_in_sentence : Thus, malignancy of MCF-7 is highly dependent on monosialyl-Gb5, and its activation of cSrc and FAK in GEM.[PMID:12401210]
publication : 12401210|16995838|[https://pubmed.ncbi.nlm.nih.gov/27318475 27318475 27318475]
definition : alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp is a linear amino hexasaccharide comprising β-D-glucose at the reducing end with at the 4-position a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety, α(2→3)-sialylated at the terminal galactosyl residue.[CHEBI:62313]
term_xref : GTC:G32254QI|GlycoEpitope:EP0099|GlycoMotif:GGM.000080|CID:73427363|CHEBI:62313
synonyms : GL-7 globoseries ganglioside (SSEA-4)|Monosialyl Gb5|Sialosyl galactosyl globoside|GL-7 globoseries ganglioside|SSEA-4
function :
disease_associations : renal cell carcinoma/RCC[GlycoEpitope:EP0099]
wikipedia :
essentials_of_glycobiology :


Mono-sulfated globopentaosylceramide

G80193TN
term (main_entry) : Mono-sulfated globopentaosylceramide 
glycan_dictionary_accession : GSD000126
glytoucan_accession  : G80193TN
term_in_sentence : Mono-sulfated globopentaosylceramide from human kidney.[PMID:2777788]
publication : 2777788
definition :
term_xref : GlycoMotif:GGM.000072|GTC:G80193TN
synonyms : Monosulfated globopentaosylceramide
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Mono-sulfated globotetraosylceramide

G05297EK
term (main_entry) : Mono-sulfated globotetraosylceramide 
glycan_dictionary_accession : GSD000127
glytoucan_accession  : G05297EK
term_in_sentence : Mono-sulfated globotetraosylceramide from human kidney.[PMID:2559078]
publication : 2559078
definition :
term_xref : GlycoMotif:GGM.000073|GTC:G05297EK
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


N-acetyl GM2

term (main_entry) : N-acetyl GM2 
glycan_dictionary_accession : GSD000128
glytoucan_accession  : G79389NT
term_in_sentence : The appearance of the N-acetyl GM2 antigen correlated well with the degree of differentiation of the cancer cells in patients with squamous cell carcinoma and adenocarcinoma of the lung.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861 3167861]]
publication : [https://pubmed.ncbi.nlm.nih.gov/3167861 3167861 3167861]|2153431|[https://pubmed.ncbi.nlm.nih.gov/25673107 25673107 25673107]
definition : beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp is a branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220]
term_xref : GTC:G79389NT|GlycoEpitope:EP0051|CID:45266845|CHEBI:59220
synonyms :
function : The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.[CHEBI:59220]
disease_associations : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]
wikipedia :
essentials_of_glycobiology :


N-acetyllactosamine (Type 1)

G00056MO
term (main_entry) : N-acetyllactosamine (Type 1)
glycan_dictionary_accession : GSD000181
glytoucan_accession  : G00056MO
term_in_sentence : The N-acetyllactosamine type 1 (LacNAc type 1, Galβ1,3GlcNAc) is a well-known precursor of several important blood group epitopes, such as Lewis A, Lewis B, or sialyl Lewis A [1], which are involved in many biological processes, e.g., fertilization [2] and pathogen adhesion [3]. [PMID:28796164]
publication : [https://pubmed.ncbi.nlm.nih.gov/28796164 28796164 28796164]|[https://pubmed.ncbi.nlm.nih.gov/28167527 28167527 28167527]
definition :
term_xref : GTC:G00056MO|GlycoMotif:GGM.000005
synonyms : LacNAc type 1|Type 1 LN|Type-1 lactosamine
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


N-acetyllactosamine (Type 2)

G00055MO
term (main_entry) : N-acetyllactosamine (Type 2)
glycan_dictionary_accession : GSD000129
glytoucan_accession  : G00055MO
term_in_sentence : Utilising a fast and sensitive screening method based on imidazolium-tagged probes, we report unprecedented reversible activity of bacterial beta1,4-galactosyltransferases to catalyse the transgalactosylation from lactose to N-acetylglucosamine to form N-acetyllactosamine in the presence of UDP.[PMID:31165848]
publication : 31165848|31126011|28796164|6236210|9751793|29740087|9151975|10567443|21472942|26477523|6548353|28167527|20056550|7737204|22052010|10223649|11323440|10420596|7766648|25257940|17977857|15556936|26541999|23650594|9692202|29429899|21062783|25034434|8985145|28503789|8720464/
definition : N-acetyllactosamine is a beta-D-galactopyranosyl-(1→4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. It is also known as galb1-4glcnacb or lacnac, belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group. N-Acetyllactosamine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Acetyllactosamine exists in all living organisms, ranging from bacteria to humans.[CHEBI:16153,HMDB0001542]
term_xref : GTC:G00055MO|CID:439271|CHEBI:16153|MeSH:C000458|GlycoMotif:GGM.000001
synonyms : LacNAc|Type 2 LN
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


N-Glycolyl-GM2

G56478LD
term (main_entry) : N-Glycolyl-GM2 
glycan_dictionary_accession : GSD000130
glytoucan_accession  : G56478LD
term_in_sentence : The monoclonal antibodies MK2-34 and MK1-16 (both IgM), which specifically detect N-glycolyl GM2 and N-acetyl GM2, respectively, were generated by immunizing mice with liposomes containing monophosphoryl lipid A, trehalose dimycolate, and the antigenic ganglioside.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3167861 3167861 3167861]]
publication : [https://pubmed.ncbi.nlm.nih.gov/3167861 3167861 3167861]|11861662|17980710|3731079|[https://pubmed.ncbi.nlm.nih.gov/25673107 25673107 25673107]
definition : (2S,4S,5R,6R)-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-5-[(2-hydroxyacetyl)amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of carbohydrates and carbohydrate derivatives.[CHEBI:151464]
term_xref : GTC:G56478LD |GlycoEpitope:EP0052|CID:91845742|CHEBI:151464|GlycoEpitope:GGM.000096
synonyms :
function :
disease_associations : choriocarcinoma[GlycoEpitope:EP0052]|teratocarcinoma|[GlycoEpitope:EP0052]yolk sac tumor[GlycoEpitope:EP0052]
wikipedia :
essentials_of_glycobiology :


N-linked glycans

G78059CC
term (main_entry) : N-linked glycans 
glycan_dictionary_accession : GSD000131
glytoucan_accession  : G78059CC
term_in_sentence : Our study identifies extracellular N-linked glycans-and the glycoprotein neurexin 1β specifically-as key modulators of neuronal uptake of αSacetyl, drawing attention to the potential therapeutic value of αSacetyl-glycan interactions.[PMID:31211781]
publication : 31211781|28384382|30305477|31364612|26899268|29945790|29652253|29723274|30962676|29778448|25325701|31100702|28898525|22944671|19277537|24473128|17957771|27554083|15189166|11269317|[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919 19577919]|24303005|12042249|22191536|28324664|25965797|25434632|30484244|28110657|[https://pubmed.ncbi.nlm.nih.gov/29865036 29865036 29865036]|20129637|27346875|30280442|26911286|22491358|26582281|26398792|31548313|31066275|28331984|25482090|[https://pubmed.ncbi.nlm.nih.gov/28518173 28518173 28518173]|30733536|22326428|30063825|30315103|21558494|[https://pubmed.ncbi.nlm.nih.gov/31676555 31676555 31676555]|31256374
definition : The carbohydrate portion of a glycoprotein that has a glycan linked through the nitrogen of an asparagine side-chain.[CHEBI:59520]
term_xref : GTC:G78059CC|CID:70679232|CHEBI:70967
synonyms :
function : N-glycans modulate the function of several cell surface proteins which involved in migration, adhesion and which are responsible for regulating myelination.[PMID: 25151374]|Affect transportation of the glycosylated proteins in the Golgi.[PMID: 25151374]|Affects cell-cell interaction, adhesion, expression, proper folding.[PMID: 25151374]|extracellular N-glycans act as key modulators of neuronal uptake of αacetyl [PMID: 31211781].
disease_associations : Rheumatoid arthritis[PMID:17392038]|Type 1 Diabetes[PMID:29146600]|Lung Cancer[PMID: 23766031]
wikipedia :
essentials_of_glycobiology : Chapter 14


Nonfucosylated

term (main_entry) : Nonfucosylated 
glycan_dictionary_accession : GSD000132
glytoucan_accession  :
term_in_sentence : In the carbohydrate moiety , alpha-subunit from normal pregnancy hCG contained nonfucosylated , mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027]]]
publication : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027]]|30258536|23554380|16675584|26747427|22457527|24362443|19657637|8811881|19218011|20022111|17363544|17368483|20564614|27054024|28397880|[https://pubmed.ncbi.nlm.nih.gov/31490688 31490688 31490688]|31860772|17012310|29633346|9442021|30350565|30296068|31800250|30021910|31133022|[https://pubmed.ncbi.nlm.nih.gov/29224385 29224385 29224385]|[https://pubmed.ncbi.nlm.nih.gov/28630087 28630087 28630087]|26444434|31697975|30991260
definition : glycans without a fucose component/monosaccharide residue.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Nonfucosylated biantennary

term (main_entry) : Nonfucosylated biantennary 
glycan_dictionary_accession : GSD000133
glytoucan_accession  :
term_in_sentence : Structural analysis combining methylation-mass spectrometry and 400 MHz 1H-n.m.r. spectrometry of oligosaccharide alditols released from human leucocyte lactotransferrin shows the presence of two disialylated and non-fucosylated biantennary glycans of the N-acetyl-lactosaminic type.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2390069 2390069 2390069]]
publication : [https://pubmed.ncbi.nlm.nih.gov/2390069 2390069 2390069]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027]]|1375510|9101715|[https://pubmed.ncbi.nlm.nih.gov/2390069 2390069 2390069]|2332109
definition : A biantennary glycan with two GlcNAc branches linked to the core and no fucose appears.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 9


Nonfucosylated biantennary N-Linked structures

term (main_entry) : Nonfucosylated biantennary N-Linked structures 
glycan_dictionary_accession : GSD000134
glytoucan_accession  :
term_in_sentence : The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027]]]
publication : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027] [https://pubmed.ncbi.nlm.nih.gov/9449027 9449027 9449027]]
definition : A biantennary N-linked glycan with two GlcNAc branches linked to the core and no fucose appears.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Nonfucosylated triantennary

term (main_entry) : Nonfucosylated triantennary 
glycan_dictionary_accession : GSD000135
glytoucan_accession  :
term_in_sentence : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans.[PMID:7679920]
publication : 7679920|23274891
definition : A triantennary N-linked glycan with three GlcNAc branches linked to the core and no fucose appears.
term_xref :
synonyms :
function : Appears in human alpha-fetoprotein (AFP).[PMID:7679920]
disease_associations : hepatocellular carcinoma[PMID:7679920].
wikipedia :
essentials_of_glycobiology :


Nonsialylated

term (main_entry) : Nonsialylated 
glycan_dictionary_accession : GSD000136
glytoucan_accession  :
term_in_sentence : The pattern of nonsialylated oligosaccharides was used for interpretation of the fully sialylated species using bioinformatics tools. From pooled human plasma, we find 90, 101, and 64 different glycan compositions for genetic variants ORM1*F1, ORM1*S, and ORM2, respectively. Glycan structures carry dominantly between 15 and 16 sialic acids indicating an almost complete termination of all antenae with sialic acid.[PMID:30295034]
publication : 14533820|1377689|9705949|30788437|28090561|12498371|26839900|[https://pubmed.ncbi.nlm.nih.gov/31490688 31490688 31490688]|2656426|30295034|31545048|12381155|25730103|26787879|25646460|[https://pubmed.ncbi.nlm.nih.gov/29224385 29224385 29224385]|26063435|26954852|32889432|2825412|27504786|22431161
definition : A glycan which is not sialylated.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


O-fucose glycans

G39294YF
term (main_entry) : O-fucose glycans 
glycan_dictionary_accession : GSD000137
glytoucan_accession  : G39294YF
term_in_sentence : Recently, a number of laboratories have shown that O-fucose glycans on the epidermal growth factor (EGF)-like repeats of the Notch extracellular domain modulate Notch signaling.[PMID:12417415]
publication : 19594638|30690220|[https://pubmed.ncbi.nlm.nih.gov/18952191 18952191 18952191]|22415200|12417415|16400812|18948267|21464368|20816394|30207383|20301232|27129198|17132502|22492969|30030822|30214079|26175457|25378397|18272537|28729422|11524432|31722217|23045360|24803430|28876865|25700513|32518939|30523691|18227520|20816217|24909690|17964136|12036964|27268051|15653671|19948734|31590629|32201074|15189151|17263732|32913123|12909620|[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176 28785176]|17132500|22949680|25053492|28939751
definition : Form of glycosylation where the protein is modified by a fucose residue and can be extended futher to form a tetrasaccharide in certain cases. alpha-linked o-fucose have a consensus motif of C2X4(s/T)C3 where C2 and C3 are conserved cysteines number 2 and 3 respectively of the EGFR like repeats. [Essentials of Glycobiology:Chapter13]
term_xref : GTC:G39294YF|GlycoEpitope:EP0005
synonyms :
function : modification of Notch signaling.[GlycoEpitope:EP0005]
disease_associations :
wikipedia :
essentials_of_glycobiology :


O-GlcNAc

G49108TO
term (main_entry) : O-GlcNAc 
glycan_dictionary_accession : GSD000138
glytoucan_accession  : G49108TO
term_in_sentence : A better understanding of the mechanisms of OGT/OGA action would enable us to derive therapeutic benefits of resetting cellular O-GlcNAc levels within an optimal range.[PMID:30464755]
publication : 30464755|29049853|29594839|31654859|29404877|30105004|30669087|29790000|28408483|26862193|30523150|30037904|28408480|29352075|29456783|29577901|29223644|28638491|30221662|29904918|32155042|30298013|31630803|31847126|29784830|30181664|28768194|30134155|25336654|30356792|30199580|32329777|28408494|29774032|29044951|23836420|20301273|29772801|28922739|30100348|30793403|30657688|31237748|29756380|29954943|30018219|32207184|25566193|30626734|24759912|
definition : Form of glycosylation which exclusively occurs in the mitochondrial, cytoplasmic or nuclear compartments of the cell where the protein is modified by a GlcNAc monosaccharide on the serine or threonine residues and is generally not modified or elongated further to form more complex structures. [Essentials of Glycobiology:Chapter19]
term_xref : GTC:G49108TO|GlycoEpitope:EP0004|CID:24139|HMDB:HMDB0000803
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


O-linked glycans

term (main_entry) : O-linked glycans 
glycan_dictionary_accession : GSD000139
glytoucan_accession  :
term_in_sentence : Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29865036 29865036 29865036]]
publication : [https://pubmed.ncbi.nlm.nih.gov/29865036 29865036 29865036]|30952424|31611643|[https://pubmed.ncbi.nlm.nih.gov/19577919 19577919 19577919]|32019882|19139197|26184710|11159917|21536259|25186198|19277556|22261557|24115046|18725413|[https://pubmed.ncbi.nlm.nih.gov/15966855 15966855 15966855]|24256304|25477510|10359703|24406064|22259135|29279989|[https://pubmed.ncbi.nlm.nih.gov/15966855 15966855 15966855]|30619255|9673446|[https://pubmed.ncbi.nlm.nih.gov/31676555 31676555 31676555]|28745859|28196325|27975143|30591584|[https://pubmed.ncbi.nlm.nih.gov/28518173 28518173 28518173]|17522109|[https://pubmed.ncbi.nlm.nih.gov/26328495 26328495 26328495]|32178593|27529638|24663386|22474328|28096352|27496768|[https://pubmed.ncbi.nlm.nih.gov/18952191 18952191 18952191]|11135308|24917611|11532966|22786570|11891229|18332077|26867212|26925665|16769205|23475718|16005634|[https://pubmed.ncbi.nlm.nih.gov/28785176 28785176 28785176]
definition : The carbohydrate portion of a glycoprotein that has a glycan linked through the hydroxyl oxygen of serine, threonine, hydroxylysine or hydroxyproline side-chains.[CHEBI:59521]
term_xref : CHEBI:59521
synonyms :
function : Affects several important activities like protein stability, modulation of signaling molecules and enzyme activity.[PMID:9673446]
disease_associations :
wikipedia :
essentials_of_glycobiology :


O-linked mannose

G59126YU
term (main_entry) : O-linked mannose 
glycan_dictionary_accession : GSD000140
glytoucan_accession  : G59126YU
term_in_sentence : Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2) catalyzes the first step toward the functional matriglycan structure on alpha-dystroglycan that is responsible for binding extracellular matrix proteins and certain arenaviruses.[PMID: 27932460]
publication : 27932460|24526361|25381909|26644575|23851827|28810660|19054127|23929950|21684258|22608994|28973932|24733390|31851597|29884773|28711406|14577328|21089343|14617637|9838223|17072003|[https://pubmed.ncbi.nlm.nih.gov/26328495 26328495 26328495]|11181560|31949166|31988979|20362685|27733679|27493216|20044576|30643095|29732660|10580142|14568618|28079948|15467391|27812179|23761899|25737452|32930586|25381372|23434682|16857188|21452199|19429925|25361541|24297939|30322079|23428289|28427937|22746206|27533452|17502374|20816174|27496765
definition : O-linked glycans that are initiated by the addtion of a Man residue to Ser or Thr. Subsequent extension of the Man defines the O-Man core type, either M1, M2, or M3. The M1 type is initated by addition of a GlcNAc in β-linkage to the 2 position of the Man residue. M2 is initiated by addition of another GlcNAc to the 6 position of the M1 core. M3 is initiated by the addition of a GlcNAc in β-linkage to the 4 position of the Man residue. M1 and M2 type core glycans can be extended and branched with Gal, Fuc, Sialic Acid, and GlcA. The M3 core is uniquely extended by a multienzyme system to generate the matriglycan polysaccharide, a protein-specific modification found only on alpha-dystroglycan. [CHEBI:87761]
term_xref : GlycoMotif:GGM.000055|GTC:G59126YU|CHEBI:87761|GlycoEpitope:EP0002|CID:91859038
synonyms : O-mannosyl glycan
function :
disease_associations : MEB/muscle-eye-brain disease[GlycoEpitope:EP0002]|WWS/walker-warburg syndrome |muscular dystrophy[GlycoEpitope:EP0002]|neuronal migration disorder[GlycoEpitope:EP0002]|Muscle-Eye-Brain disease (MEB) and Walker-Warburg Syndrome (WWS) have mutations in genes encoding glycosyltransferases needed for O -mannosyl oligosaccharide synthesis[GlycoEpitope:EP0002]|Muscular dystrophy and neuronal migration disorder are caused by mutations in a glycosyltransferase, POMGnT1.[GlycoEpitope:EP0002]
wikipedia :
essentials_of_glycobiology :


P1 antigen

G12460DL
term (main_entry) : P1 antigen 
glycan_dictionary_accession : GSD000141
glytoucan_accession  : G12460DL
term_in_sentence : The P1 antigen was disovered in 1927 by Landsteiner and Levine, and Pk and NOR were described in 1951 and 1982, respectively.[PMID: 24046920]
publication : 29622537|26773500|24046920|6207232|8550516|6609976|6375319|817855|2428855|3312011|15364312|1937801|7729906
definition : An amino pentasaccharide consisting of α-D-galactose, β-D-galactose N-acetyl-α-D-glucosamine, β-D-galactose, and β-D-glucose residues joined in sequence with ((1→4)-, (1→4)-, (1→3)- and (1→4)-linkages, respectively.[CHEBI:68484]
term_xref : GlycoMotif:GGM.000069|GTC:G12460DL|CID:71296137|CHEBI:68484|SugarBind_Ligand:160
synonyms :
function :
disease_associations : Shigellosis[SugarBind_Ligand:160]
wikipedia :
essentials_of_glycobiology : Chapter 23


Para-Forssman glycolipid

G51699SI
term (main_entry) : Para-Forssman glycolipid 
glycan_dictionary_accession : GSD000142
glytoucan_accession  : G51699SI
term_in_sentence : A novel pentaglycosyl ceramide containing di-beta-N-acetylgalactos-aminyl residue (Para-Forssman glycolipid) isolated from human erythrocyte membrane. [PMID:6814203]
publication : 6814203
definition : GalNAcβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1→1Cer [https://doi.org/10.1016/S0040-4039(01)93814-6]
term_xref : GlycoMotif:GGM.000085|GTC:G51699SI|CID:56836111|KEGG:G00096|SugarBind_Ligand:19|CHEBI:151565
synonyms :
function :
disease_associations : Actinomycosis[SugarBind_Ligand:19]
wikipedia : https://en.wikipedia.org/wiki/P1PK_blood_group_system
essentials_of_glycobiology :


Paragloboside

G58896AZ
term (main_entry) : Paragloboside 
glycan_dictionary_accession : GSD000143
glytoucan_accession  : G58896AZ
term_in_sentence : Galactosyltransferase activities in sera of cancer patients were determined by assaying the formation of paragloboside from UDP-galactose and lactotriaosylceramide immobilized on microtiter plates by means of the enzyme-linked immunosorbent assay using a monoclonal antibody, H-11, directed to paragloboside. [PMID: 1551117]
publication : 3345524|850070|10569746|30624951|29438961|6816790|1551117|6865961|25039255
definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is α.[CHEBI:65257]
term_xref : GlycoMotif:GGM.000077|GTC:G58896AZ|CID:21670519|CHEBI:65257|GlycoEpitope:EP0075|SugarBind_Ligand:15
synonyms :
function :
disease_associations : Pharyngitis[SugarBind_Ligand:15]|Tracheobronchitis[SugarBind_Ligand:15]|Gonorrhea[SugarBind_Ligand:15]|Actinomycosis[SugarBind_Ligand:15]|Diarrhea[SugarBind_Ligand:15]|Hemorrhagic colitis[SugarBind_Ligand:15]|Chronic gastritis[SugarBind_Ligand:15]|Peptic ulcers[SugarBind_Ligand:15]|Gastric cancer[SugarBind_Ligand:15]|Influenza[SugarBind_Ligand:15]
wikipedia :
essentials_of_glycobiology : Chapter 14


Paucimannose

term (main_entry) : Paucimannose 
glycan_dictionary_accession : GSD000144
glytoucan_accession  :
term_in_sentence : The galactosylation of core fucose (GalFuc epitope) in paucimannose and complex-type N-glycans is characteristic of protostome organisms, including flatworms (planarians).[PMID:29475940]
publication : 29475940|29803109|12603202|31817246|31719144|21057214|31932305|17132514|30382146|27731363|31325506|25746926|26513758|16522637|21169367|25190359|27928741|22496646|27384337|16897177|15228383|27379103|27189951|23475714|24907509|20558211|28060516|20441997|27720757|28817611|24550396|19494052|19515361|[https://pubmed.ncbi.nlm.nih.gov/28630087 28630087 28630087]|31320997|30651366|30253927|25922361|31655162|18056652|24467287|32367383
definition : Any N-linked glycan derivative with composition Man1-4Fuc0-1 GlcNAc2, in which the chitobiose core (GlcNAc2) is intact. Found in relatively large amounts in invertebrates and plants, they are formed by removal of the non-reducing terminal GlcNAc (\added by GlcNAcT1) from GlcNAcMan3-5GlcNAc2 by a Golgi hexosaminidase and subsequent removal of Man residues by Golgi mannosidases. Pauscimannose glycans have also been detected in vertebrates.[CHEBI:144386]
term_xref : CHEBI:144386
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Polysialic acid

term (main_entry) : Polysialic acid
glycan_dictionary_accession : GSD000182
glytoucan_accession  :
term_in_sentence : Polysialic acid (PSA) is a carbohydrate composed of a linear polymer of α2,8-linked sialic acids, primarily attached to the Neural Cell Adhesion Molecule (NCAM). [PMID:36076963]
publication : 36076963|35222358
definition :
term_xref : GlycoMotif:GGM.000252
synonyms : polySia|PSA
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Sd(A)/Cad

G41052GC
term (main_entry) : Sd(A)/Cad 
glycan_dictionary_accession : GSD000145
glytoucan_accession  : G41052GC
term_in_sentence : The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2.[PMID:24112972]
publication : 24112972|11577689|30067891|15361072
definition : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, β-D-galactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the galactose residue of which is also linked (1→4) an N-acetyl-β-L-galactosamine residue. [CHEBI:71561]
term_xref : GlycoMotif:GGM.000051|GTC:G41052GC|CID:70698375|CHEBI:71561
synonyms : Sd^a /Cad
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 9


SDlex

G19619KS
term (main_entry) : SDlex 
glycan_dictionary_accession : GSD000146
glytoucan_accession  : G19619KS
term_in_sentence : Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure.[PMID: 3341453]
publication : 30226570|3341453|12725333
definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:148203]
term_xref : GlycoMotif:GGM.000032|GTC:G19619KS|CID:91856705|CHEBI:148203
synonyms : Sdlex|SDLe^x|SDLex
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 14


Seminolipid

G72548RZ
term (main_entry) : Seminolipid 
glycan_dictionary_accession : GSD000147
glytoucan_accession  : G72548RZ
term_in_sentence : A concise total synthesis of seminolipid, a sulfoglycolipid, has been achieved; key features include regioselective, tin-free sulfation of allyl β-d-galactopyranoside using 2,6-bis(trifluoromethyl)phenylboronic acid as protective reagent, stereoselective epoxidation, and site-selective acylation. [PMID: 31353379]
publication : 31353379|31736776|12810822|19582571|19542524|20670037|15659616|20817833|870059|10801776|21965315|8095813|1280685|4690236|34199863|4207869|2373957|845131
definition :
term_xref : GlycoMotif:GGM.000062|GTC:G72548RZ
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 14


Sialopentaosylceramide

G13224CR
term (main_entry) : Sialopentaosylceramide 
glycan_dictionary_accession : GSD000148
glytoucan_accession  : G13224CR
term_in_sentence : Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosap[PMID: 2139874]
publication : 2139874
definition : A ganglioside in which the oligosaccharide portion is composed of a pentasaccharide containing one or more sialic acid residues.[CHEBI:36542]
term_xref : GlycoMotif:GGM.000097|GTC:G13224CR|CID:91859576|CHEBI:148045|KEGG:G00883|CHEBI:36542
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Sialosyl paragloboside

G50123ZO
term (main_entry) : Sialosyl paragloboside 
glycan_dictionary_accession : GSD000149
glytoucan_accession  : G50123ZO
term_in_sentence : Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG).[PMID:8862128]
publication : 8862128|7236652|2370108|3133978|2905604|1749114|1573418
definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-D-GlcpNAc with β configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.[CHEBI:71612]
term_xref : GlycoMotif:GGM.000081|GTC:G50123ZO|CID:91845504|KEGG:G01429|CHEBI:151914
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Sialyl Lewis a

G00053MO
term (main_entry) : Sialyl Lewis a 
glycan_dictionary_accession : GSD000150
glytoucan_accession  : G00053MO
term_in_sentence : By comparing the serum O-glycan profiles from healthy controls with those of cancer patients, we identified a marker candidate, core 1 sialyl Lewis A (NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal) (abbreviated C1SLA), whose concentration appeared to be weakly correlated with CA19-9 values.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888 26641888]]
publication : [https://pubmed.ncbi.nlm.nih.gov/26641888 26641888 26641888]|31424423|26530370|17760270|18343410|16033091|8829184|11907351|20592391|[https://pubmed.ncbi.nlm.nih.gov/26641888 26641888 26641888]|24128856|30249386|10773785|16149606|10996727|10436809|10667238|7720892|7630017|10612415|9836451|12511721|22623153
definition : A sialyated version of Lewis A with a branched structure of amino tetrasaccharide consisting of a sialyl residue, linked (2→3) to a galactosyl residue that in turn is linked (1→3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.[CHEBI:62681]
term_xref : GTC:G00053MO|GlycoEpitope:EP0008|CID:53356732|CHEBI:62681|GlycoMotif:GGM.000024
synonyms : SLea|CA19-9|CA19-9 antigen|SLe^a|Slea
function : The carbohydrate determinants,Sialyl Lea and Sialyl Lex,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0008]
disease_associations : pancreatic adenocarcinoma[GlycoEpitope:EP0008]|hepatocellular cancer[GlycoEpitope:EP0008]|cholangiocellular cancer[GlycoEpitope:EP0008]|gastric cancer|[GlycoEpitope:EP0008]colorectal cancer[GlycoEpitope:EP0008]|ovarian cancer[GlycoEpitope:EP0008]|lung cancer[GlycoEpitope:EP0008]|breast cancer[GlycoEpitope:EP0008]|uterine cancer[GlycoEpitope:EP0008]
wikipedia :
essentials_of_glycobiology :


Sialyl Lewis x

G00054MO
term (main_entry) : Sialyl Lewis x 
glycan_dictionary_accession : GSD000151
glytoucan_accession  : G00054MO
term_in_sentence : As sialyl Lewis X is a lignad of the selectin family, it has been proposed that sialyl Lewis X-rich colon cancer cells metastasize to the liver by adhesion to selectins on hepatic endothelial cells.[PMID:12828079]
publication : 12828079|[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172 8940172]|10075923|19054801|[https://pubmed.ncbi.nlm.nih.gov/9642161 9642161 9642161]|31054033|15229399|29061785|16033070|10728707|9556613|[https://pubmed.ncbi.nlm.nih.gov/8940172 8940172 8940172]|9298692|18607721|22593503|25944902|[https://pubmed.ncbi.nlm.nih.gov/9642161 9642161 9642161]|15780091|20401888
definition : A sialylated version of Lewis X antigen expressed on cell surfaces with structure alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAcis α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta. It is a ligand for selectins. [MESH:[https://pubmed.ncbi.nlm.nih.gov/2030970 2030970 2030970],CHEI:71622]
term_xref : GTC:G00054MO |GlycoEpitope:EP0012|CID:44456859|CHEBI:71622|MESH:[https://pubmed.ncbi.nlm.nih.gov/2030970 2030970 2030970]|GlycoMotif:GGM.000022
synonyms : SLe(x)|SLe^x|SLex|Slex
function : Sialyl Lex was shown to be a specific ligand on human leukocytes for vascular E- and P-selectins,and was shown to mediate leukocyte recruitment.[GlycoEpitope:EP0012]|The determinant is also frequently expressed on human cancer cells,and is involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[GlycoEpitope:EP0012]
disease_associations : colon cancer[GlycoEpitope:EP0012]|colorectal cancer[GlycoEpitope:EP0012]
wikipedia :
essentials_of_glycobiology :


Sialyl Lewis x-i

G06597DS
term (main_entry) : Sialyl Lewis x-i 
glycan_dictionary_accession : GSD000152
glytoucan_accession  : G06597DS
term_in_sentence : Univariate analysis showed that survival of NSCLC patients with high (more than 100 units/ml) sialyl Lewis X-i antigen levels was significantly poorer than that of patients with low antigen levels (P = 0.0001).[PMID:9815711]
publication : 9815711|9730796|11867833|9713476|2819663|9372327|9615762|1352835|2575680|9330526|8753037|2210805|12680155|11974864|10453898|2565704|17144590
definition :
term_xref : GTC:G06597DS|GlycoEpitope:EP0043|CID:91855346|CHEBI:147019
synonyms :
function : hematogenous metastasis[GlycoEpitope:EP0043]|the progression of inflammation[GlycoEpitope:EP0043]
disease_associations : lung cancer[GlycoEpitope:EP0043]|ovarian cancer[GlycoEpitope:EP0043]|pancreatic adenocarcinoma[GlycoEpitope:EP0043]
wikipedia :
essentials_of_glycobiology :


Sialyl T antigen

G65562ZE
term (main_entry) : Sialyl T antigen 
glycan_dictionary_accession : GSD000153
glytoucan_accession  : G65562ZE
term_in_sentence : The expression and functional analysis of the sialyl-T antigen in prostate cancer.[PMID:32583304]
publication : 32583304|31897478|31719620|[https://pubmed.ncbi.nlm.nih.gov/10365852 10365852 10365852]|25727149|11523928|20407596|25464017|30864133|26391208|19811634|29796594|23725156|8905873|11192238|18275089|27037304|11949946|15604091|24118321
definition : Alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-alpha-D-GalpNAc is alpha-Neup5Ac-(2→3)-beta-D-Galp-(1→3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha. It has a role as an epitope.[CHEBI:65257]
term_xref : GlycoMotif:GGM.000013|GTC:G65562ZE|CID:44611726|CHEBI:65257
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Sialylated biantennary

term (main_entry) : Sialylated biantennary 
glycan_dictionary_accession : GSD000154
glytoucan_accession  :
term_in_sentence : Simbucus nigra agglutinin or an antibody specific to sialylated lactosamine with a preference for Neu5Acalpha2-6Gal rather than Neu5Acalpha2-3Gal reduced sperm binding to oviduct isthmic cells, as did occupying putative receptors on sperm with sialylated biantennary glycans.[PMID:23115267]
publication : 23115267|31510952|29265394|31589880|3979568|26045275|29029079|30252064
definition : A binantennary glycan with one or two sialic acid residues as non-reducing terminal residues on one or both antennae. [RN]
term_xref :
synonyms : sialyl biantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Sialylated complex-type

term (main_entry) : Sialylated complex-type 
glycan_dictionary_accession : GSD000155
glytoucan_accession  :
term_in_sentence : By using 1H-NMR spectroscopy we were able to establish that our product contains a single N-linked biantennary , fully sialylated complex-type oligosaccharide , typical of human hepatomas.[PMID:1694115]
publication : 1694115|15201278|30471292|30969765|11058758|28342150
definition : Complex N-linked glycan that have added GlcNAc residues at both the α-3 and α-6 mannose sites and do not contain mannose residues apart from the core structure but with sialic acid residues.
term_xref :
synonyms : sialo-complex type
function : enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes [PMID: 15201278] Appears in IgG-Fc.[PMID:20647032 ]
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 10


Sialylated LacdiNAc

G55583HW
term (main_entry) : Sialylated LacdiNAc
glycan_dictionary_accession : GSD000192
glytoucan_accession  : G55583HW
term_in_sentence : The major non-reducing epitopes in the complex-type glycans are: Gal beta 1-4GlcNAc (lacNAc), GalNAc beta 1-4GlcNAc (lacdiNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacNAc), NeuAc alpha 2-6Gal beta 1-4GlcNAc (sialylated lacdiNAc), Gal beta 1-4(Fuc alpha 1-3)GlcNAc (Lewisx), and GalNAc beta 1-4(Fuc alpha 1-3)GlcNAc (lacdiNAc analogue of Lewisx).[PMID:7592613]
publication : 7592613|34192302|19756298|16286643
definition :
term_xref : GlycoMotif:GGM.000050
synonyms : sialylated-LacdiNAc|Sialylated LDN
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Sialylated tetraantennary

term (main_entry) : Sialylated tetraantennary 
glycan_dictionary_accession : GSD000156
glytoucan_accession  :
term_in_sentence : A small amount of sialylated tetraantennary oligosaccharide was detected.[PMID:16321355]
publication : 16321355|1940447|27501865
definition : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of one sialic acid residues.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Sialyl-Tn antigen

G36123IU
term (main_entry) : Sialyl-Tn antigen 
glycan_dictionary_accession : GSD000157
glytoucan_accession  : G36123IU
term_in_sentence : The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.[PMID:23035012]
publication : 23035012|29273237|15770530|31595388|26617889|1720922|15466199|10971172|14652017|8616877|1543361|16965854|21566901|9269833|9834267|24970145|22367369|10778170|30018351|28628803|16149605|32134186|28632300|11308020|[https://pubmed.ncbi.nlm.nih.gov/10365852 10365852 10365852]|17195456|23567325|11014575|2342728|8575847|1851822|11735169|20960853|7846011
definition : N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-alpha-D-galactosamine is an N-acetyl-alpha-neuraminyl-(2→6)-N-acetyl-D-galactosamine in which the carbon bearing the anomeric hydroxy group has alpha configuration. It has a role as an epitope. It derives from a N-acetyl-alpha-D-galactosamine and a N-acetyl-alpha-neuraminic acid.[CHEBI:61818]
term_xref : GTC:G36123IU|GlycoEpitope:EP0022|CID:51351800|CHEBI:61818
synonyms :
function : apoptosis of monocyte-derived dendritic cells[GlycoEpitope:EP0022]|decrease of adhesion and increase of migration[GlycoEpitope:EP0022]|increase of tumor growth[GlycoEpitope:EP0022]|associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.[GlycoEpitope:EP0022]
disease_associations : anaplastic meningioma[GlycoEpitope:EP0022]|Barrett's esophagus[GlycoEpitope:EP0022]|bladder cancer[GlycoEpitope:EP0022]|breast cancer[GlycoEpitope:EP0022]|colon cancer[GlycoEpitope:EP0022]|colorectal cancer[GlycoEpitope:EP0022]|erythroblastic leukemia[GlycoEpitope:EP0022]|esophageal cancer[GlycoEpitope:EP0022]|gastric cancer[GlycoEpitope:EP0022]|helicobacter pylori chronic gastritis(HpCG)[GlycoEpitope:EP0022]|liver cancer[GlycoEpitope:EP0022]|iterome cancer[GlycoEpitope:EP0022]|ovary tumor[GlycoEpitope:EP0022]|pancreas cancer[GlycoEpitope:EP0022]
wikipedia :
essentials_of_glycobiology : Chapter 56


SLex Core 2 O-glycan

term (main_entry) : SLex Core 2 O-glycan 
glycan_dictionary_accession : GSD000158
glytoucan_accession  : G97345NY
term_in_sentence : In particular, the sLeX-modified core 2 O-glycan structure C2-O-sLeX has been directly demonstrated to confer significantly higher affinity selectin binding than sLeX.[PMID:15596301]
publication : 15596301
definition :
term_xref : GlycoMotif:GGM.000053|GTC:G97345NY
synonyms : SLe^x Core 2 O-glycan
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


SSEA-1

G85497PI
term (main_entry) : SSEA-1 
glycan_dictionary_accession : GSD000159
glytoucan_accession  : G85497PI
term_in_sentence : Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas.[PMID:27550342]
publication : 27550342|25564944|30987116|10778174|19427293|24923741|28092949|16499901|10470652|18787210|2885312|16149609|17003364|27363517|15505339|27990704|2568298|20491542|23572256|1977666|9553168|[https://pubmed.ncbi.nlm.nih.gov/20458727 20458727 20458727]|2566639|14577357|20960856|15547746|9096265|30639212|1357195|1359630|20181261|20508065|2907526|22624699|22988836|17183690|27188587|7908065|10400391|6137429|1979260|2898921|14736812|30919971
definition :
term_xref : GTC:G85497PI |GlycoEpitope:EP0042|CID:91851144|CHEBI:154343
synonyms :
function : This determinant is specifically recognized by the antibody raised against stage-specific embryonic antigen-1 (SSEA-1)[GlycoEpitope:EP0042]. The SSEA-1 antibody requires Lex hapten carried by i-antigenic structure (e.g.,nor-nLc6Cer).[GlycoEpitope:EP0042]
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 10


SSEA-3

G25129BT
term (main_entry) : SSEA-3 
glycan_dictionary_accession : GSD000160
glytoucan_accession  : G25129BT
term_in_sentence : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926 31817926]]
publication : [https://pubmed.ncbi.nlm.nih.gov/31817926 31817926 31817926]|30271856|32684574|26677875|23175153|32525407|[https://pubmed.ncbi.nlm.nih.gov/29227830 29227830 29227830]|[https://pubmed.ncbi.nlm.nih.gov/18773292 18773292 18773292]|25561682|10837462|[https://pubmed.ncbi.nlm.nih.gov/2412924 2412924 2412924]|[https://pubmed.ncbi.nlm.nih.gov/21149348 21149348 21149348]|[https://pubmed.ncbi.nlm.nih.gov/17008424 17008424 17008424]|[https://pubmed.ncbi.nlm.nih.gov/2874662 2874662 2874662]|[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543 25171543]|31304790|31642560|30484221|30525067|21161592|27325407|28170296|29637816|[https://pubmed.ncbi.nlm.nih.gov/27318475 27318475 27318475]|31346146|7648586|24236059|21964054|27456773|30558911|21559451|29312455|27549315|30599359|6141938|28883415|30733757|26041528|16643871
definition : An amino trisaccharide consisting of β-D-galactopyranose, 2-acetamido-2-deoxy-β-D-galactopyranose and α-D-galactopyranose residues joined in sequence by (1→3) glycosidic linkages.[CHEBI:149071]
term_xref : GTC:G25129BT|GlycoEpitope:EP0039|CID:91855781|CHEBI:149071|GlycoMotif:GGM.000079
synonyms :
function :
disease_associations : embryonal carcinoma[GlycoEpitope:EP0039]|teratocarcinoma[GlycoEpitope:EP0039]|yolk sac carcinoma[GlycoEpitope:EP0039]
wikipedia :
essentials_of_glycobiology :


SSEA-4

G84263XI
term (main_entry) : SSEA-4 
glycan_dictionary_accession : GSD000161
glytoucan_accession  : G84263XI
term_in_sentence : Glycosphingolipids (GSLs), such as the globo-series GSLs stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, and Globo-H, are specifically expressed on pluripotent stem cells and cancer cells, and are known to be associated with various biological processes such as cell recognition, cell adhesion, and signal transduction.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926 31817926]]
publication : 27845370|[https://pubmed.ncbi.nlm.nih.gov/31817926 31817926 31817926]|26295543|[https://pubmed.ncbi.nlm.nih.gov/25171543 25171543 25171543]|25978997|30296654|25853231|24862940|31243630|28736232|22895512|24578244|29478902|23574147|23768762|27797400|[https://pubmed.ncbi.nlm.nih.gov/29227830 29227830 29227830]|[https://pubmed.ncbi.nlm.nih.gov/18773292 18773292 18773292]|25123923|22924692|22665977|23330736|31831622|31916611|[https://pubmed.ncbi.nlm.nih.gov/2412924 2412924 2412924]|16033656|24866102|[https://pubmed.ncbi.nlm.nih.gov/20458727 20458727 20458727]|[https://pubmed.ncbi.nlm.nih.gov/21149348 21149348 21149348]|26940129|[https://pubmed.ncbi.nlm.nih.gov/17008424 17008424 17008424]|[https://pubmed.ncbi.nlm.nih.gov/2874662 2874662 2874662]|23301556|27836003|19118716|24550271|32988880|22743677|20683402|17062733|23570331|30310530|31545316|23509763|24364909|18273440|28985528|22266579
definition :
term_xref : GTC:G84263XI|GlycoEpitope:EP0044|CID:91845478|CHEBI:154843
synonyms :
function :
disease_associations : teratocarcinoma[GlycoEpitope:EP0044]
wikipedia :
essentials_of_glycobiology : Chapter 47


Sulfated LacdiNAc

G18464VS
term (main_entry) : Sulfated LacdiNAc
glycan_dictionary_accession : GSD000191
glytoucan_accession  : G18464VS
term_in_sentence : The mRNA expression of the enzymes related to the formation of sulfated LacdiNAc:β(1,4)-N-acetylgalactosaminyltransferases 3 (B4GALNT3) and 4 (B4GALNT4), carbohydrate sulfotransferases 8 (CHST8) and 9 (CHST9); and β(1,4)-galactosyltransferase 1 (B4GALT1) in these cells was confirmed by RT-PCR (Fig. S4).[PMID:31558607]
publication : 31558607|27318476|19756298|11279168|26688390
definition :
term_xref : GlycoMotif:GGM.000049
synonyms : 4'-O-sulfated LacdiNAc|4'-sulfated LDN|sulfated LDN
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :


Sulfatide

term (main_entry) : Sulfatide 
glycan_dictionary_accession : GSD000162
glytoucan_accession  : G72548RZ
term_in_sentence : In a previous study we found that sulfatide was efficient in lowering HIV-1 viral loads in SCID mice engrafted with human fetal liver/thymus tissues (SCID-hu).[PMID:23550344]
publication : 23550344|18465098|26542149|15158666|10434709|22619219|29676479|30196830|16143863|1052451|30400820|29887538|26981544|17986152|31739035|19941861|24578319|30531843|25645724|31197846|22821828|27861899|31037952|23593400|23604989|17855742|25966258|25989600|9657940|29497057|12838515|25170267|9878314|20554435|1410493|26585924|17257892|17044925|21089387|11445552|22977233|21437360|17179664|6273571|8370675
definition :
term_xref : GlycoMotif:GGM.000063|GTC:G72548RZ
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 47